Printer Friendly

Dissecting major signaling pathways throughout the development of prostate cancer.

1. Introduction

The long-term ineffectiveness of current treatments for prostate cancer (PCa) has spurred an increasing interest in understanding the molecular mechanisms that underlie PCa tumorigenesis [1]. Currently, PCa is considered the most common nonmelanoma neoplasia among men [2-4]. According to the current trends in population growth, the incidence of PCa will exceed 1.7 million new cases by 2030 [5]. In the United States, nearly 2.8 million men are potentially living with this condition, and approximately 240,000 new cases were diagnosed in 2012 [3]. PCa predominately affects elderly men with higher incidence [6], and it is more prevalent in Western countries [7], where the average life expectation is over 75 years old. In developing countries like Brazil, PCa has recently surpassed the population incidence of breast cancer, and it has become the most common tumor malignancy, with approximately 50,000 new cases occurring per year [4, 5]. Yet, there is a considerable heterogeneity in the mortality rates and incidence among different countries, probably due to the variable penetrance of some risk factors such as age, race, genetics (family history), diet and environmental factors [8], and also behavioral factors, like frequent consumption of dairy products and meat [9], smoking, and sexual behavior [10].

Several agents such as diet, life habits, and exposure to chemical agents have been correlated with risk of PCa development [8]. For instance, a broad study performed by a PCa prevention trial group (Seattle, USA) has found high correlations between the intake of polyunsaturated fat and the development of aggressive PCa [11]. Corroborating this study, a strong correlation has been found (over 50%) between obesity and aggressive PCa development in both African and Caucasian men [12]. In Brazil, for instance, PCa is more frequently related to higher socioeconomic classes [13]. The increase in animal fat consumption and reduction in fiber consumption, along with sedentarism, have been suggested to be related to higher risks of PCa progression, along other types for cancers [14]. Thus, fat consumption appears to be a major risk factor for PCa. The association between pesticide exposure and hormone-related cancers, such as PCa, has been extensively debated since the late 1990s [15]. On the other hand, several studies have inversely correlated mild exposure to sunlight to higher mortality or PCa incidence [16]. However, the exact factors responsible for a potential induction of PCa are still not fully understood.

The development of prostatic tumor in men is generally slow, taking up to 4 to 10 years to develop a 0.4 inch-size tumor [17]. PCa begins when the semen-secreting prostate gland cells mutate into tumor cells, proliferating at higher mitotic levels. Initially, the prostate cells begin to proliferate leading to tumor formation in the peripheral zone of the prostate gland. Over time these cancer cells eventually multiply to further invade nearby organs, such as the seminal vesicles, rectum, bladder and urethra [18]. During the initial metastatic stages, malignant cells from the primary tumor detach from their original site and migrate through blood and lymphatic vessels [19]. In the later stages, cancer cells eventually spread to more distal organs, including bones, liver, and lung [18].

PCa treatment has been conducted primarily by surgery and/or radiotherapy due to the intimate organ localization [4, 20]. A prostatectomy usually leads to an excellent prognosis with low risk of death from PCa after surgery [21]. However, deregulated production and secretion of growth factors by stromal cells within the PCa microenvironment, as well as mutations in androgen signaling pathway components and further physiological modifications, including angiogenesis, local migration, invasion, intravasation, circulation, and extravasation of the tumor, potentially lead to systemic recurrence of the cancer, including the appearance of focal tumor in advanced stage [22-26]. In this case, the preferred treatment is based on androgen-deprivation therapy (ADT), mostly including a luteinizing-hormone-releasing hormone (LHRH) [20]. In advanced PCa, ADT still remains the most effective therapy in initial stages, despite its temporary effectiveness (ingeneral, between 18 and 24 months) [20,27].

In order to study PCa, a variety of cell lines mimicking androgen-dependent and androgen-independent carcinogenic formations have been extensively used [28]. These cell lines have enabled researchers to directly test a series of antitumor drug candidates, such as tumor apoptosis inducers [29] or enhancers of antitumor immune response [30], as well as to evaluate the genomic foundations of PCa [31] and to further decipher the biological characteristics within cancer development [32, 33]. Alongside the in vitro studies, several animal models have been developed in order to confirm in vitro results by using a more clinically relevant approach [34, 35]. Mouse models for PCa can be obtained by systemic induction of gene mutations [36], xenografts [37], or by doxycycline-based inducible systems to overexpress certain target genes like in the case of AKT, which in turn induces tumorigenesis [38].

Many genetic alterations may be accountable for PCa induction, whereas mutations in genes responsible for the expression of proteins that participate in a variety of cell signaling processes can affect the decision of cell death or survival [39]. In this review, we will discuss the role of major cellular signaling pathways in the progression of PCa and some potential strategies to prevent this malignant outcome.

2. The Androgen Receptor Signaling Pathway in Prostate Cancer

2.1. Pathway Description. The androgen receptor (AR) signaling pathway promotes the differentiation of epithelial cells into male urogenital structures and encodes proteins that are necessary for the normal function of the prostate and for the initiation and maintenance of spermatogenesis [20, 40]. AR is a nuclear receptor that acts as a transcription factor [20], which is formed by four distinct functional domains like many other steroid-hormone receptors (Figure 1). The first region is composed of an N-terminal domain (NTD) that is constitutively active and has a transcriptional activation function (AF-1), executed by two transcriptional activation units (TAU-1 and TAU-2). The second region is a highly conserved DNA-binding domain (DBD), responsible for DNA binding specificity and for facilitating the dimerization and stabilization of the AR-DNA complex [20, 27]. The COOH-terminal ligand-binding domain (LBD) is another receptor site that is moderately conserved and equally important to mediate the binding to steroid hormones, which is the primary feature of the AR signaling pathway 20]. This site is also responsible for the direct binding between AR and the chaperone complex (Hsp90), which keeps the receptor in an inactive state but in a spatial conformation that allows affinity for androgens [41]. Upon binding to androgens, Hsp dissociates and releases AR from this complex, which further dimerizes and then translocates to the nucleus [27]. A fourth AR region contains the hinge region, a short amino-acid sequence that separates LBD from DBD and possesses a nuclear localization signal (NLS). This region is also important for the AR translocation to the nucleus through the interaction with the cytoskeletal protein Filamin-A (FlnA) [20], whose cytoplasmic localization is correlated with metastatic and hormone-refractory phenotype [20, 42].

2.2. Pathway Disruptions Associated with PCa and Therapeutic Targets. One of the major causes of CRPCa is AR overexpression, which can be related to gene amplification or transcriptional and/or translational upregulation and decreased degradation. AR gene amplification is observed in approximately 80% of the CRPCa cases, being the most common genetic alteration in this type of cancer [43]. However, gene amplification can only partially explain AR overexpression, and other mechanisms that promote this enhancement have been investigated [27]. AR regulates many genes through the binding of the AR-ligand complex to the DNA, specifically to androgen receptor binding sites (ARBSs) or androgen-responsive elements (AREs). These binding sites might be close to the target genes or acting as distal enhancers. During PCa progression, many androgen-regulated genes including UBE2C, CND1, p21, and p27 are up-regulated [43, 44]. In most of CRPCa conditions, where AR overexpression is found, prostate cells show more sensitivity to lower concentrations of the ligand [45].

AR mutations are rare in the initial phases of PCa, but theyareverycommon in CRPCa [43]. These mutations might broaden AR specificity towards nonandrogenic molecules, or they can bypass the necessity of a ligand for proper transcriptional activity [27]. A considerable number of AR mutations have been characterized, showing that the promiscuous behavior of the receptor culminates in activation by adrenal androgens and other steroids hormones, including dehydroepiandrosterone (DHEA), progesterone, estrogens, and cortisol [27]. This phenomenon allows the prostatic epithelial cells to grow in an androgen-refractory way [40, 43, 46]. For this, there are three particular AR regions where mutations appear to give specific properties (Figure 1). The first region is between residues 701 and 730, and it enables resistance to adrenal androgens, glucorticoids and progesterone [27, 43], and mutations like L701H, V715M, and V730M are responsible for affecting these properties [27, 43]. In the second region, between residues 874-910, a T877A mutation has been described as the most frequent in CRPCa [43]. This alteration appears to affect the AR ligand specificity by changing the stereochemistry of the binding pocket, which expands the spectrum of ligands able to bind AR. This allows other hormones like DHEA, estrogen, progesterone, cortisone, and cortisol to activate AR [27, 40, 43]. Another mutation (H874Y) is also responsible for enhancing the transcription sensitivity of AR towards steroids like adrenal androgens or antiandrogens [43]. The third mutational site occurs between residues 670-678, located at the boundary of the hinge and LBD regions, that enhances the transactivation activity of AR in response to dihydrotestosterone (DHT). Other mutations in the amino terminus also occur but at a low frequency [27].

Transcription factors play a key role in AR expression and act positively or negatively in gene regulation. For instance, cAMP response element-binding proteins (CREB) have been reported to significantly increase during PCa progression, which ultimately enhances AR transcriptional levels [46]. The proto-oncogene Myc is well known to be involved in cancer formation [46] and it also participates in AR transcription, acting as a predictor of biochemical recurrence after radical prostatectomy (RP) [46, 47]. The member of the activator protein-1 (AP-1) c-Jun is known to suppress AR expression, but it also acts as a coactivator of this receptor [46, 47]. Another transcription factor that positively regulates AR transcription is FOXO3a, which binds to the Foxo-response element in the AR promoter region. The Lymphoid enhancer-binding factor 1 (LEF1) is a nuclear transducer that indicates a link between Wnt signaling and PCa, as Wnt1 leads to activation of LEF1 and it increases AR transcription [46]. Other transcription factors, like NF-[kappa]B and Twist-1, have a positive correlation with AR expression, suggesting a key role in the progression and in the CRPCa state 46].

Another mechanism to bypass the requirement of ligands for AR activity is the presence of splice variants of AR transcripts. Alternative splicing events occur in approximately 90% of human genes and such events are evident in PCa [27, 43] where, in fact, it is an important mechanism of PCa resistance to AR-targeted therapy and further progression to CRPCa. Recent studies have identified several AR splice variants, and, despite having slightly different structures, a common characteristic is the absence of the LBD and the AF-2 domain in these isoforms [41]. The absence of LBD leads to loss of repression activity of this domain in the receptor, and potential hormone-independent AR activity [41]. It has been suggested that some AR variants may have an exclusive cytoplasmic function, although it has been demonstrated that truncated AR variants still show a nuclear localization that is enough to support transcriptional activity [41]. It has also been demonstrated that these AR variants can access the nucleus independently of the Hsp90 chaperone complex [41]. The clinical relevance of these variants is currently under investigation, and, due to the frequent identification of these splice variants in PCa metastases and CRPCa [27], these molecules could be envisioned as potential therapeutic targets.

Alterations of AR transcriptional activation induce deregulated proliferation and survival of prostate cells. For instance, it has been reported that androgens enhance the transcription of SENP1, a member of SUMO-specific protease family, showing that the regulation of AR signaling through this protease is based on a positive feedback mechanism [48]. Similarly, the regulation of the cell cycle regulator cyclin D1 by SENP1 contributes to cancer progression [49]. Therefore, SENP1 has emerged as an important prognostic marker and also a therapeutic target [38, 49]. Moreover, considering that the AR receptor is a phosphoprotein, changes to its phosphorylation profile would clearly have an impact on its function [20,27,40]. The use of pharmacological agents that modulate the AR posttranslational portfolio could be considered as an alternative approach for further interventions.

3. The NF-[kappa]B Pathway in Prostate Cancer

3.1. Pathway Description. The nuclearfactorkappa B(NF-[kappa]B) signaling pathway is involved in a variety of physiopathological conditions, including inflammation, autoimmune disorders, and cancer. In humans, the NF-[kappa]B family is composed of fivemembers: p65 (RelA), p100/p52, p105/p50, c-Rel and RelB (Figure 2(a)). NF-[kappa]B proteins form homo- or heterodimeric structures that, after activation, function as transcriptional factors through binding to [kappa]B enhancer sites along the DNA. The canonical NF-[kappa]B pathway involves the phosphorylation of the inhibitory I[kappa]B proteins by the I[kappa]B kinase complex (IKK) (composed of the catalytic subunits IKK[alpha] and IKK[beta], and the regulatory scaffolding protein NEMO), which results in the ubiquitination and further degradation of I[kappa]B by the proteasome, thus releasing the NF-[kappa]B dimers to translocate to the nucleus and activate [kappa]B-responsive target genes. In contrast, a non-canonical NF-[kappa]B pathway is detected in a more cell-specific fashion (including lymphoid tissue and immune-related cells), and it involves an IKK[alpha]-dependent p100 processing instead of the typical I[kappa]B degradation. The noncanonical pathway is activated by specific stimuli that include Lymphotoxin-[beta] (LT[beta]) and B cell-activating factor (BAFF), whereas the canonical pathway is activated by a broader spectrum of stimuli, such as tumor necrosis factor [alpha] (TNF-[alpha]) and interleukin 1 (IL-1) and is often related to tumorigenesis, including leukemias, lymphomas, and some solid tumors [50-54]. Some NF-[kappa]B target genes have important antiproliferative and apoptotic roles and may contribute to the development, progression, and resistance of certain tumor cells.

3.2. Pathway Disruptions Associated with PCa and Therapeutic Targets. Molecular strategies that target NF-[kappa]B have been shown to suppress prostate cancer, in terms of both prevention and further therapy [55-58]. For instance, the effect of specific IKK inhibitors in the growth and survival of androgen-dependent and independent PCa cell lines has been determined. The results indicate that, regardless of the AR status and androgen dependency, cell growth is remarkably affected [59]. Thus, the identification of NF-[kappa]B responsive genes linked to PCa progression represents a critical step toward a better understanding and treatment of this disease. Some genetic alterations have been identified by the differential mRNA expression between tumor tissues versus normal tissues. For example, during androgen-independent tumorigenesis in the prostate, NF-[kappa]B expression is elevated at both mRNA and protein level [60]. These studies indicate that the NF-[kappa]B pathway can be constitutively activated in PCa, since an increased expression of interleukin 6 (IL-6) in androgen-independent PCa cell lines (PC-3 and DU145) was consistently observed. This deregulation of IL-6 expression in prostate cancer cells is in fact mostly mediated by the constitutive NF-[kappa]B activation 61], and this activation occurs through signal transduction involving the upstream effectors NF-[kappa]B inducing kinase (NIK) and IKK. Therefore, NF-[kappa]B also targets a transcription regulatory element of the prostate-specific antigen PSA, which is an important marker for development and progression of PCa [62, 63].

The proinflammatory cytokine TNF-[alpha], a prototypical NF-[kappa]B inducer and also a downstream target gene, is highly expressed in PCa, and the TNF receptors TNFR1 and TNFR2 are also expressed at higher levels in the tumor epithelium when compared to normal prostate epithelium (Figure 2(b)) [64]. The levels of TNF-[alpha] in the serum are associated with the pathological data and the prognosis of PCa patients [65]. High expression of TNF-[alpha] has been correlated with increased survival and proliferation of PCa cells, angiogenesis, metastasis, and changes in the response to chemotherapeutic agents [66]. Experiments using PC-3 and DU145 cell lines treated with psoralidin (TNF-[alpha] inhibitor) indicate that this cytokine could be one potential therapeutic target. TNF-[alpha] inhibition by psoralidin inhibits NF-[kappa]B via p65 and other upstream molecules, including the survival protein families IAPs (inhibitor of apoptosis proteins) [67]. The IAP proteins inhibit two major pathways that normally initiate the activation of the cysteine protease caspases, the mitochondrial (intrinsic) and the death receptor (extrinsic) pathways. The combined inhibition of IAPs and TNF-[alpha] could be attractive for PCa therapy, since IAPs modulate apoptotic events and TNF-[alpha] affects cell survival and proliferation via NF-[kappa]B [68].

Recent clinical data and in vitro studies have suggested that NF-[kappa]B directly interferes with AR signaling. NF-[kappa]B is associated with increased AR expression and higher binding activity in androgen-independent xenografts [69]. In fact, AR has been described as a NF-[kappa]B target gene, whereas p65/RelA activity causes an increase of AR at both mRNA and protein levels [70]. Moreover, endogenous AR expression can be induced by p65 in human prostate cancer cells, and this induction is associated with increased expression of downstream AR targets and enhanced growth and/or survival of prostate cancer cells [70]. Complex formation including the non-canonical p52 and AR has also been described, where it causes an increase in nuclear localization and binding of AR to DNA even in the absence of its ligand. This ligand-independent AR activation has similarities to the non-canonical NF-[kappa]B signaling, since both pathways depend on IKK1 activity to phosphorylate the p100 precursor and by STAT3 phosphorylation [71]. NF-[kappa]B and STAT3 share a subset of target genes during tumorigenesis, including PAI-1, Bcl-3, Bcl-2, and GADD45[beta]. For this, the cooperation between STAT3 and NF-[kappa]B pathways is required [ 72], in such a way that NF-[kappa]B members physically interact with STAT3. This interaction can result in a synergy of specific gene transcription or repression regulated by NF-[kappa]B/STAT3. It has been suggested that nonphosphorylated STAT3 can bind to the NF-[kappa]B complex, thus facilitating its activation independently of IKK activity, supporting the idea that STAT3 may prolong the presence of active NF-[kappa]B dimers in the nucleus. Thus, STAT3 may represent an important mechanism that ensures continuous NF-[kappa]B activation in cancer cells 72].

The regulation of NF-[kappa]B by the tumor suppressor gene p53 has also been observed in many types of hematopoietic and solid tumors [73]. The interaction between p53 and NF-[kappa]B reveals that, despite its role as a tumor suppressor, NF-[kappa]B becomes activated after reactivation of p53 even when the p53-induced apoptosis requires the participation of NF-[kappa]B. Thus, activation of NF-[kappa]B in apoptosis is additionally related to a hyperactivation of p53 [73]. Because NF-[kappa]B and p53 can be eventually activated by the same stimuli, the balance of their activities is crucial for cell fate decision. An important mechanism of communication between these two pathways is the binding competition for CBP and p300, which are necessary for the selective activation of these factors [74].

4. The PI3K/AKT Pathway in Prostate Cancer

4.1. Pathway Description. The Phosphoinositide 3-kinase/ AKT (PI3K/AKT) pathway is a key signal transduction pathway that links multiple classes of membrane receptors to many essential cellular functions, such as cell survival, proliferation, and differentiation [75-77]. PI3K molecules are divided into three major classes: class I (IA and IB) molecules, which have one catalytic and one regulatory subunit and can bind to receptor tyrosine kinases, G-protein coupled receptors and oncogenic proteins, such as small G protein RAS, to transduce their signals, and class II and III molecules which have a single catalytic subunit and can bind to several receptors, such as RTKs or cytokine receptors (class III molecules have been shown as important mediators of signaling through the mammalian target of rapamycin, mTOR). After activation of PI3K, these molecules can induce recruitment and activation of the serine/threonine-specific protein kinase AKT (also called protein kinase B, PKB) through phosphorylation-induced activation of transmembrane phosphatidylinositol (4,5) bisphosphate (PIP2) into phosphatidylinositol (3,4,5) trisphosphate (PIP3). PIP3 can recruit AKT through its pleckstrin homology domain [78, 79], a conserved protein module identified in many proteins involved in cell signaling or as cytoskeleton constituents. Activated AKT can subsequently phosphorylate and activate several other proteins, such as mTOR, glycogen synthase kinase 3, and FOXO members (the forkhead box family of transcription factors). Ultimately, AKT's action induces and regulates a large array of cellular processes [80, 81]. Considering that PI3K/AKT signaling is related to cell survival and proliferation, it is reasonable to link PI3K/AKT to cancer development.

4.2. Pathway Disruptions Associated with PCa and Therapeutic Targets. PI3K/AKT pathway is deregulated in the majority of solid tumors [82]. In PCa, it has been estimated that PI3K/AKT/mTOR signaling is up-regulated in 30%-50% of the cases, often due to the loss of PTEN function [83, 84], which leads to AKT hyperactivation. PTEN (phosphatase and tensin homolog) is responsible for the dephosphorylation of PIP3 to PIP2 and, in this way, negatively controls the activity of PI3K/AKT signaling. Interestingly, it is not clear whether or how direct mutations in AKT can lead to PCa [85]. PTEN is haploinsufficient in PCa, and its genetic dose is linked to PCa progression, in which total loss of function can be correlated with more advanced PCa, as seen in artificially created mouse models [86]. Complete PTEN inactivation in the prostate leads to a noninvasive PCa phenotype in mouse models, suggesting that other mutations might drive the appearance of more invasive tumors [87]. In fact, mutations in p53 or in the cyclin-dependent kinase inhibitor p27KIP1, when combined with loss of PTEN, have been linked to more aggressive PCa in vivo [87, 88]. Besides PTEN gene deletion, other mechanisms seem to contribute to loss of PTEN function. For instance, the action of microRNAs (miRNAs)--small, single-stranded RNA sequences which function as posttranscriptional regulators of gene expression--on PTEN inactivation has been recently described, with the characterization of miR-22 and miR-106b~25 as PTEN-targeting miRNAs aberrantly expressed in PCa [89]. It is also known that nuclear exclusion of PTEN is important for the development of tumors, including PCa [90]. In fact, it has been described that nuclear PTEN interacts with the anaphase-promoting complex (APC/C) and induces its association with CDH1 (APC/C activator protein), thereby enhancing the suppressive capacity of the APC-CDH1 complex to advance cell division [91], thus indicating a role for nuclear PTEN in PCa suppression.

The AKT hyperactivation induces high proliferative levels and resistance to apoptosis, an example of which is TRAIL resistance. TRAIL is a member of the tumor necrosis factor superfamily that specifically promotes apoptosis in cancer cells [92]. Indeed, treatment of PCa cells with the PI3K inhibitor LY294002 induces sensitization of these cells to TRAIL-induced apoptosis [93]. The excessive PI3K/AKT activation observed in PCa cells is accompanied by the presence of certain PI3K subunits that are not usually expressed in non-hematopoietic cells, such as p110[delta]. Augmented p110[delta] expression is correlated with inhibition of PTEN activity and further AKT activation [94]. Besides p110[delta], transgenic mice with constitutive expression of p110[delta] indicate that this molecule can be also linked to neoplasia formation [95].

PI3K/AKT pathway seems to act in conjunction with other proteins implicated in PCa cell growth. For example, AKT interacts with MST1, a hippo-like serine-threonine kinase [96]. Mst1 plays a critical role in the regulation of programmed cell death and it has been implicated in PCa development [96]. Interestingly, MST1 has been detected in AR-chromatin complexes, and forced expression of MST1 reduces AR binding to androgen-responsive elements along the PSA promoter [97]. MST1 also suppresses PCa cell growth in vitro and tumor growth in vivo [97]. AKT is able to phosphorylate a highly conserved residue [Thr.sup.120] of MST1, which leads to inhibition of its kinase activity and nuclear translocation, as well as the autophosphorylation of [Thr.sup.183] [98], having a positive role in PCa progression. Another example relates to a non-membrane tyrosine kinase called Acetate Kinase (Ack1) that is recruited by the upstream receptors and activates AKT through Tyr-176 phosphorylation, favoring the development of PCa [99]. Also, the polycomb group silencing protein Bmi1 can be phosphorylated by AKT, which enhances its oncogenic potential in PCa. Overexpression of Bmi1 can act in combination with PTEN haploinsufficiency to induce invasive carcinogenic formation in the prostate [100]. Recently, it was described that the deficiency of the Sprouty protein 2 (SPRY2) acts with the epidermal growth factor receptor (EGFR) system (RTK) and loss of PTEN to drive hyperactivation of PI3K/AKT via enhanced RTK trafficking in PCa [101]. It is also important to note that insulin-like growth factor (IGF) is an upstream effector on AKT signaling, and IGF up-regulation (which activates AKT) could promote the development of PCa in vivo [102,103], suggesting an interrelationship between IGF and AKT signaling in PCa. Finally, the Myc oncogene, a downstream target of PI3K/AKT pathway, commonly upregulated in many types of cancer [104], appears to act synergistically with AKT in the development of prostate tumorigenesis by altering, for instance, its sensitivity to mTOR inhibitors [105]. The implications of PI3K/AKT signaling in PCa are detailed in Figure 3.

In the context of PCa, a variety of new drugs targeting deregulation of the PI3K/AKT pathway have been developed. Natural products such as Ethanolic Neem Leaf Extract (ENLE) [106], [beta]-Caryophyllene Oxide [107], and Dietary flavonoid fisetin [108] have been described as having anti-PI3K/AKT activity in PCa cells. Other drugs, such as curcumin, can inhibit several signaling pathways including AKT [109-112]. Synthetic drugs, such as KN-93, can inhibit PCa cell growth in an androgen-independent manner, by activation and production of reactive oxygen species (ROS), which prevent AKT activation [113]. Other drugs, like GDC0980, can inhibit PCa cell proliferation through direct inhibition of class I PI3K and mTORC1/2 [114]. HIF-1 proteins are regulators of transcriptional responses against hypoxia and equally important in angiogenesis and tumor growth. An HIF-1a inhibitor has been described to inhibit the PI3K/AKT pathway in PCa cell lines [115]. Another example is Gambogic Acid, which limits PCa development through inhibition of both PI3K/AKT and NF-[kappa]B pathways [116]. Several mTOR inhibitors have been tested to control the development of androgen-independent PCa [117]. It should be noted that there are currently several AKT inhibitors in clinical trials [118]. For instance, Celecoxib, an inhibitor of cyclooxygenase 2 (COX-2), is described to prevent AKT phosphorylation by inactivating its upstream kinase PDK1 [119]. Perifosine, a phospholipid analogue, can also arrest PCa cell cycle in G1/S or G2/M through AKT inhibition, although the mechanism of inactivation is still not fully understood (but possibly in a PDK1-independent manner) [120]. Genistein, a natural soy-based isoflavone, can inhibit AKT directly, subsequently inhibiting NF-[kappa]B activation and inducing apoptosis of PCa cells [121]. On the other hand, the deregulated PI3K/AKT pathway during PCa progression appears to be a reason for the resistance against some anticancer drugs; an example is the resistance to sunitinib in CRPCa, which is correlated with the loss of PTEN expression 122].

5. The JAK/STAT Pathway in Prostate Cancer

5.1. Pathway Description. Janus Kinase/signal transducers and activators of transcription (JAK/STAT) pathway is recognized as an important membrane-to-nucleus cascade, which may be activated by a wide variety of stimuli such as reactive oxygen species, cytokines, and growth factors [123-127]. JAK/STAT is one of the main cascades required for normal development and cell homeostasis, as well as in the control of cell proliferation, differentiation, cell migration, and apoptosis [124]. Specifically, this pathway is essential to regulate many physiopathological processes including hematopoiesis, gland development, immune response, adipogenesis, and sexually dimorphic growth [128,129]. Briefly, the signaling activation occurs when specific inducers (e.g., IL-6) binds to and induces the oligomerization of respective receptor subunits (e.g., cytokine receptors), leading to signal propagation by phosphorylation of the receptor-associated tyrosine kinases, known as JAK1-3 and Tyk2 [130, 131]. Particularly, JAK activation occurs when the receptor subunit comes into close proximity (after ligand recognition) and allows the cross-phosphorylation of these tyrosine kinases. Subsequently, activated JAKs induce the phosphorylation of the receptor that now serves as a docking site for additional JAK targets including their major substrates known as signal transducer and activator transcription factors (STATs). STAT proteins have a dual function of signal transduction and transcription activation downstream of phosphorylation events. Indeed, STAT phosphorylation permits the dimerization of other STATs, culminating with the translocation to the nucleus mediated by importin a-5 and the Ran nuclear import system. Inside the nucleus, the dimerized STATs bind to specific regulatory sequences along the DNA, leading to activation or repression of target genes [132-135].

5.2. Pathway Disruptions Associated withPCa and Therapeutic Targets. The family of STAT transcription factors is constitutively activated in many human tumors. In this sense, these proteins control various cellular events such as proliferation, differentiation, and cell survival. Extensive studies have indicated that this pathway is upregulated in a broad range of cancers [136-140]. A particular member, STAT3, has been shown to be constitutively active in a number of human tumor cell lines as well as primary tumors, including haematological malignancies [141]. For instance, constitutive activation of STAT3 has been related to breast cancer susceptibility cancer 1 (BRCA1) expression in certain tumor cell lines [142]. Additionally, mutations in BRCA genes have been shown to increase predisposition to breast, ovarian, and prostate cancers [139,143-145]. Both BRCA1 and BRCA2 are related to biological processes including DNA repair, control of cell-cycle checkpoint, and transcriptional regulation. Specifically, BRCA1 performs distinct but more general functions, working as a sensor/signal transducer and as an effector component in response to DNA damage by homologous recombination, while BRCA2 function is more restricted to DNA repair, modulating the activation of RAD51 recombinase, which is also required for homologous recombination [139,146,147]. It has been demonstrated that in PCa cells, BRCA1 interacts with JAK1/2, leading to STAT3 phosphorylation and culminating in the induction of cell proliferation and inhibition of apoptotic cell death [142].

STAT3 also targets other genes associated with cell cycle regulation [141, 148]. Upregulation of antiapoptotic STAT3 induces a subset of Bcl-related genes, including Bcl-2, Bcl-XL, Survivin, and Mcl-1, which have been described in PCa and many other tumors [141]. Another STAT3 target gene is the proangiogenic vascular endothelial growth factor (VEGF), involved in tumor invasion and spreading, which directly regulates several matrix metalloproteinases enzymes implicated in tumor cell invasion [141,149-152]. Moreover, high levels of STAT3 in both malignant and normal tissues adjacent to the tumor have been detected, suggesting that STAT3 activation may occur before any detectable histological changes in the prostate [153]. Additionally, the inhibition of JAK/STAT3 signaling suppresses PCa cell growth and induces apoptosis [154]. In fact, STAT3 inhibition has been suggested as a good strategy to promote the control of cell proliferation and, consequently, tumor growth and metastasis formation [155].

IL-6 is another factor that has been found to be upregulated in the serum of PCa patients. IL-6 signaling is important to modulate cell growth and differentiation and immune-mediated resistance against infections. Unbalanced IL-6 production has a role in several diseases, such as osteoporosis, atherosclerosis, autoimmune disorders, rheumatoid arthritis, psoriasis, diabetes, and cancer [156, 157]. Several studies have indicated an important role of IL-6 in promoting PCa progression. PCa cells have upregulated expression of both IL-6 and its receptor IL-6R [158], as well as elevated circulating levels of IL-6 in patients with metastatic PCa and CRPCa [159-161], correlating IL-6 production to cancer morbidity [162-164] and differential autocrine and paracrine modulation of PCa cell lines [141,164-166]. It has been shown that silencing of IL-6 expression by small-interfering RNA in PCa cell lines dramatically decreases cell growth, and this event is accompanied by downregulation of Bcl-2, Bcl-xL, and phosphorylation of AKT, MAPK, and STAT3 both in vivo and in vitro [167]. Upon IL-6 stimulation, androgen-responsive PCa cell lines also activate STAT3, which further binds to the C/EBP[delta] promoter region, inducing its expression. C/EBP[delta] is a member of the CCAAT/enhancer binding protein (C/EBP) family of transcription factors and plays a crucial role in the regulation of cell growth and fate [168-170]. In fact, C/EBP[delta] overexpression leads to inhibition of tumor growth in PCa [171]. On the other hand, after treatment with IL-6, androgen-independent PCa cells do not exhibit increased C/EBP[delta] gene expression or growth inhibition [171]. However, in PCa patients, the expression of C/EBP[delta] is significantly reduced in metastases when compared to primary PCa [172]. Altogether, the induction of C/EBP[delta] overexpression may function as an alternative of prevention and/or treatment of PCa. The implications of JAK/STAT pathway in PCa are detailed in Figure 4.

6. The MAPK Pathway in Prostate Cancer

6.1. Pathway Description. Mitogen activated protein kinases (MAPKs) comprise a family of kinases that have a major role in tumor growth and metastasis [173-175]. MAPKs can be divided into three subfamilies: the extracellular-signal-regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs), and p38 MAPKs that, together with the JNKs, compose the stress-activated protein kinase pathways [175]. All MAPKs have been linked to the regulation of intracellular metabolism, gene expression, cell growth and differentiation, apoptosis, and stress response [176-182]. There is a great body of evidence indicating that alterations in the regulation of MAPKs are extremely important in cancer development [183].

A plethora of extracellular signals initiate MAPK signaling by the binding and activation of receptor tyrosine kinases (RTKs) or G-protein coupled receptors (GPCRs) (Figure 5). In the case of ERK, the activation through these receptors leads to the recruitment of downstream effectors including growth factor receptor-bound protein 2 (Grb2) and protein tyrosine phosphatase non-receptor type 11 (PTPN11/Shp2), leading to the recruitment of Gab1 (GRB2-associated binding protein 1) and SOS (Son of Sevenless). Then, SOS protein exchanges the GDP in the Ras G-protein for a GTP. The Ras-GTP complex is able to activate the RAF kinase, a MAP-kinase-kinase-kinase (MAP3K) that is an upstream component of the ERK pathway, which in turn phosphorylates the MEK kinase (MAP2K) and, subsequently, phosphorylates and activates the next pathway component MAPK/ERK [184]. The RTKs that interact with Ras, or other members of its superfamily, are diverse and include the epidermal growth factor receptor (EGFR), c-Kit, platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and fms-related tyrosine kinase-3 (FLT-3) [185]. JNKs can be activated by the upstream MKK4 and MKK7 kinases [186, 187]. Although there are many JNK substrates, it is still challenging to identify the molecular networks regulated by the individual JNK family members. It has been found that JNK signaling can alternatively lead to apoptosis or cell survival [187-189]. Downstream targets of the MAPKs include c-Jun, c-Fos, and p53 [184]. c-Jun and c-Fos form a complex called AP-1 (activator protein 1) that acts as a transcription factor. MAPKs are able to translocate to the nucleus and then phosphorylate AP-1 transcription factors (c-Fos, c-Jun, ATF, and JDP family members) to mediate expression of target genes containing a TPA DNA response element (TRE) 190,191].

6.2. Pathway Disruptions Associated with PCa and Therapeutic Targets. MAPK/ERK pathway is shown to be activated in PCa, especially in later stages of the disease, and is often deregulated with AKT signaling [192-194]. The upstream events that lead to activation of MAPK signaling are not well defined but are possibly related to aberrant growth factor signaling [195]. Although members of the Ras family are rarely mutated in PCa [22], Ras and the MEK/ERK pathway are stimulated by EGF, IGF-1, KGF, and FGFs, which are often overexpressed in PCa [196-198]. The expression of Ras or its effector-loop mutants reduces the androgen-dependent requirement of LNCaP cells for growth and increases their PSA expression and tumorigenicity, whereas dominant negative N17-Ras can restore androgen sensitivity to the CRPCa C4-2 cell line [22,199]. Notably, expression of activated forms of Ras or Raf in the mouse prostate epithelium results in PCa formation [200,201]. Interestingly, a small percentage of aggressive PCa contains chromosome translocations involving b- or c-Raf, which results in a constitutively activated hybrid protein due to the loss of the N-terminal RAS binding domain [202], which suggests that perturbations of Ras or Raf signaling may occur in PCa through mechanisms other than activating mutations. Also, p38 signals play an important role in the adaptation of malignant cells to hypoxia by increasing the expression of the pore-forming proteins Aquaporins [203] and also by the increased resistance to apoptosis by overexpression of COX-2 [204].

MAPK and its upstream signals seem to be involved not only in PCa but also in the correct development of the prostate. For instance, FGFR2 is an RTK capable of recruiting Grb2 and Shp2 when activated, which acts as an upstream activator of the MAPK signaling pathway [205]. It has been demonstrated that FGFR2 is necessary for the embryological formation of the prostate [205]. Null mutants for Fgf10 mostly lack prostate budding [206], while conditional deletion of FGFR2 or Frs2[alpha], a downstream signaling component in prostate epithelium, results in defects in branching morphogenesis [207, 208] It has been also demonstrated that ERK 1/2 is rapidly activated in the urogenital sinus (UGS) when induced by FGF10, and the inhibition of FGFR activity mostly inactivates phosphorylated ERK 1/2 in the UGS, suggesting that FGF10 may signal through MAPK pathway [209].

Simultaneous activation of the ERK and AKT signaling pathways has been shown to promote PCa and CRPCa both in vitro and in vivo, while combined inhibition of these pathways blocks cell proliferation and leads to Bcl-2 and Bim upregulation [192, 210] (Figure 5). Therefore, the MAPK signaling pathway may be a target for PCa therapy, especially if its modulation could be achieved concomitant with other pathways, including PI3K/AKT signaling. The aim of future studies in this area might be directed toward the factors and mechanisms that account for differential function of JNK, p38, and ERK MAPKs as pro- or anti-tumoral factors. In addition, it has been shown that the AKT/mTOR and MAPK pathways participate in the development of PCa. A therapeutic strategy using both rapamycin (mTOR inhibitor) and PD0325901 (MEK1 inhibitor) is shown to inhibit cell growth in a series of PCa cell lines and also to affect tumor growth in mouse models [192]. These results have been further confirmed [211] using inhibitors of both PI3K/AKT/mTOR and RAS/MEK/ERK pathways. These observations may lead to the development of therapeutic approaches to effectively target the pro-tumoral effects of the MAPK pathways.

7. The TGF-[beta]/SMAD Signaling Pathway in Prostate Cancer

7.1. Pathway Description. The TGF-[beta]/SMAD signaling pathway is involved in the regulation of many cellular functions including cell growth, adhesion, migration, cell differentiation, embryonic development, and apoptosis [212]. Accordingly, alterations in the TGF-[beta]/SMAD signaling pathway are implicated in many human diseases such as cancer, fibrosis, and several hereditary conditions [213-215]. The pathway initiates when activated ligands (e.g., TGF-[beta]) bind to respective receptors, composed of a very diverse cysteine-rich domain, a single-pass transmembrane domain, and a significantly conserved intracellular serine-threonine kinase domain. There are two types of functional receptors that bind to the TGF-[beta] ligands, nominated as type I and type II receptors. Type II receptors are constitutively active receptors, and, upon ligand binding, they further activate type I receptors in a phosphorylation-dependent manner. The activated receptors then tetramerize and are able to recruit and activate SMAD proteins, the main effector proteins of this pathway [214-216]. SMADs are intracellular proteins that transduce signals from the TGF-[beta] superfamily of ligands to the nucleus, where they activate or suppress the transcription of target genes. There are eight known types of SMADs, which can be divided into three different classes: receptor-regulated SMADs (R-SMADs), common-mediated sMaD (Co-SMAD), and inhibitory SMADs (I-SMADs). Once the receptors are activated, they recruit R-SMADs and phosphorylate them. Phosphorylated R-SMADs can then form complexes with the Co-SMAD SMAD4. This complex is translocated to the nucleus and acts as a transcription factor for many target genes (Figure 6). The I-SMADs, SMAD6 and SMAD7, inhibit SMAD transcriptional activity and the activation of the TGF-[beta]/SMAD signaling pathway [214, 216].

7.2. Pathway Disruptions Associated withPCa and Therapeutic Targets. Despite the fact that enhanced TGF-[beta] levels have been positively associated with prostate cancer progression (Figure 6), TGF-[beta]-mediated suppression of growth and motility is also increased in metastatic CRPCa cells, and these events appear to be partially mediated by Smad2/3 signaling [217]. For instance, there is an increased sensitivity to TGF-[beta]1-mediated growth inhibition and downregulation of cyclin D in prostate-derived metastatic cell lines C4-2 and C4-2B, when compared to the nonmetastatic cell line (LNCaP cells) and robust phosphorylation and nuclear translocation of Smad2 and Smad3 in metastatic cell lines [217]. The interactions of the stromal environment and epithelial tumor cells apparently dictate PCa progression, and it is likely that TGF-[beta] pro-metastatic effects indirectly affects PCa cells through stromal cells, in contrast to its antiproliferative effect on the epithelium [217].

Using a Cre/flox-based system in mouse models, it has been observed that, in the absence of TGF-[beta]1 produced by activated [CD4.sup.+] T cells and regulatory T cells, there is inhibition of tumor growth and protection from spontaneous PCa [218]. These findings have suggested that TGF-[beta]1, produced by activated [CD4.sup.+] T cells, is necessary for tumor evasion from immune surveillance [218]. Furthermore, it is reported that LY2109761, a selective inhibitor of the TGF-[beta] type I receptor, provides anti-tumoral effects against PCa cells after growth in bone tissue [219]. In addition, increased volume in normal bone and increased osteoblast and osteoclast numbers are observed after inhibition of the TGF-[beta] type I receptor [219]. Thus, TGF-[beta]1 has been detected at higher levels in the sera of PCa patients, is associated with bone metastasis, and correlates to a poor clinical outcome [220-222]. Many other studies have also linked changes in the levels of TGF-[beta] and of pathway components to cancer progression and to further cellular responses [215, 223, 224].

Evidence for SMAD2 as a critical mediator of TGF-[beta]-induced apoptosis has been reported [225]. Silencing of Smad2 expression in NRP-152, a nontumorigenic rat prostate basal epithelial cell line, inhibits TGF-[beta]-induced apoptosis. Furthermore, rats injected with small hairpin RNA (shRNA) constructs targeting SMAD2 show palpable PCa tumors in over 80% of the injected sites by day 41 following injection [225].

The activation of the TGF-[beta] signaling pathway in an SMAD-independent manner has also been described [226]. BMP-10 (bone morphogenetic protein 10) seems to inhibit growth of PCa cells, mainly by inducing caspase-3 mediated apoptosis and preventing PCa cell migration and invasiveness through SMAD-independent signaling (Figure 6) 226]. BMP-10 overexpression in PCa cells decreases tumor cell growth, cell matrix adhesion, invasion, and migration. These effects seem to be mediated through activation of TAK1 and ERK1/2 [226]. Nodal, another TGF-[beta] ligand, has also been found to be overexpressed in some PCa cells and it can be involved in the inhibition of proliferation and induction of migration in these cells [227]. Furthermore, activin A, also known to inhibit growth of PCa cells and promote apoptosis, has been identified as a promoter of bone metastasis in PCa, possibly through SMAD signaling and concomitant elevation of the androgen receptor (AR) gene transcription [228]. Interestingly, the expression of activin A correlates with increased PSA expression, and, therefore, it might be considered as a novel biomarker or potential therapeutic target for the treatment of patients with metastatic PCa [228].

8. The Wnt Signaling Pathway in Prostate Cancer

8.1. Pathway Description. The Wnt family is composed of a large set of soluble proteins that play important roles in the embryonic developmental processes including cell proliferation, differentiation, and epithelial-mesenchymal interactions [229, 230]. Deregulations in the Wnt pathway have been implicated in cancer development in a variety of tissues including lung, skin, liver, and prostate [229, 231, 232]. Wnt proteins exert their biological effects through two signaling pathways (canonical and non-canonical), which are separated by their ability to stabilize [beta]-catenin [233]. The [beta]-catenin is a multirole protein that promotes cell proliferation by inducing gene transcription through the activation of transcription factors like T cell factor (TCF) and lymphoid enhancer factor (LEF) family of transcription factors [234]. [beta]-Catenin exists in a cytoplasmic complex with Axin, APC (adenomatous polyposis coli gene), and glycogen synthase kinase 3[beta] (GSK3[beta]), which constitute the "[beta]-catenin destruction complex." In the absence of Wnt, [beta]-catenin is phosphorylated by casein kinase I (CKIa) at Ser45; this, in turn, enables GSK3[beta] to phosphorylate serine/threonine residues 41, 37, and 33 [235]. Phosphorylation of these last two residues triggers ubiquitination of [beta]-catenin and further degradation by the proteasome ([233, 236, 237], Figure 7(a)). The binding of Wnt proteins to transmembrane Frizzled receptors (FZD) activates the Disheveled protein (DVL), leading to the dephosphorylation of Axin which then reduces the formation of cytoplasmic [beta]-catenin complexes. As a result, free [beta]-catenin accumulates in the cytosol and it is further translocated to the nucleus, where it activates TCF/LEF transcriptional factors ([238], Figure 7(b)). The [beta]-catenin/LEF/TCF complexes have been shown to interact with a variety of other nuclear factors to control specific transcriptional targets which include c-Myc, p300, CBP, Hrpt2, Foxo, Bcl9-2, reptin, pontin, c-Jun, Grouchos, Prmt2, CtBP, and cyclin D1 [239-241].

8.2. Pathway Disruptions Associated withPCa and Therapeutic Targets. The Wnt family members have been widely studied in PCa progression [241]. It has been hypothesized that PCa cells adopt embryonic signaling pathways that are generally silent in differentiated cells [242]. The role of [beta]-catenin in tumorigenesis was first established in colon carcinoma, due to its complex formation with the adenomatous polyposis coli (APC) gene product [243]. APC is a well-known tumor suppressor, which plays a central role in the Wnt signaling pathway by targeting [beta]-catenin for degradation. It has been shown that the APC gene is downregulated due to promoter hypermethylation [244], while [beta]-catenin is frequently mutated to an active form [245] and it is typically found in early stages of prostate tumor formation. Indeed, APC exerts a variety of growth regulatory functions that, if disrupted, might lead to tumor formation [235]. A mouse model in which the APC gene has been inactivated results in PCa and adenocarcinoma [246]. Alterations in the APC gene are rare, although loss of heterozygosity and mutation have been detected in some PCa samples [243, 247]. As indicated, some studies have identified the genes c-Myc and cyclin D1 as transcriptional targets activated by the [beta]-catenin signaling pathway [248, 249]. The overexpression of c-Myc and cyclin D1 increase cell growth and tumorigenicity in PCa cells, and these genes are apparently activated at the earliest phases of PCa progression [248, 249]. Noticeably, Wnt ligands are upregulated in PCa, and their expression often correlates with

aggressiveness and metastasis [250]. It has been determined that 15 out of the 19 Wnt proteins are expressed in PCa cell lines [251]. Several Wnt ligands, such as Wnt-5a and Wnt-11, can induce the [beta]-catenin-independent (non-canonical) pathway [252]. In particular, Wnt-11 is a secreted protein that modulates cell growth, differentiation, and morphogenesis during development; however, the prevalence of increased expression of Wnt-11 in tumours and the functions of Wnt-11 in PCa cells are not fully understood [253]. Recent data have shown an upregulation of Wnt-11 expression in a significant proportion of PCa tumors, and it has been positively correlated to higher Gleason scores as well as increased PSA levels [254]. Another Wnt ligand, Wnt-4, is highly expressed during embryonic development but is significantly less abundant in the adult prostate [251], suggesting that Wnt signaling might be temporally regulated during prostate development and that it can induce changes in cell fate for prostate progenitors.

Overexpression of Wnt ligands and high levels of pcatenin gene expression have been associated with advanced PCa in vitro [255]. Moreover, detection of mutant forms of [beta]-catenin has been discovered in PCa [256, 257]. A series of studies have demonstrated that mutant forms of [beta]-catenin that affect GSK3[beta]-dependent phosphorylation site (which prevents its degradation and then allows its accumulation in the cytosol) are found in 5%-7% of radical prostatectomy specimens ([250,258,259], Figure 7(c)). Another mechanism for increased [beta]-catenin expression in PCa may be loss of PTEN, which is common in advanced PCa and results in activation of the PI3K and downstream AKT signaling pathways [260]. AKT can phosphorylate and inactivate GSK3[beta], leading to stabilization and increased levels of [beta]-catenin. Indeed, GSK3[beta] suppression and subsequent [beta]-catenin stabilization have been directly demonstrated in PTEN-deficient PCa cell lines [261]. Consistently, other members of the Wnt pathway are also deregulated in PCa [262]. For instance, Frizzled-4 (FZD4, a Wnt receptor) is co-expressed in human PCa samples with the ETS-related gene (ERG). Gene fusions involving ETS transcription factors (mostly ERG) are found in roughly 50% of all PCas [254]. Further experiments have shown that FZD4 overexpression in ERG-positive PCa leads to an epithelial-to-mesenchymal transition, which is a crucial step in metastasis initiation [254].

In summary, there are several ways that the Wnt pathway can be abnormally activated in cancer, due to the large number of proteins involved in this pathway [ 257]. For this reason, there is a great potential for the development of a wide array of Wnt antagonists. Several pharmaceutical and biotechnology companies have substantial programs designed to target this pathway [260], and a variety of drugs targeting Wnt pathway are currently on the market or under development [263, 264]. Some categories of drugs include non-steroidal anti-inflammatory drugs (NSAIDs) [265], vitamin D derivatives [266], antibody-based treatments [259], and other small molecule inhibitors [266, 267].

9. Conclusions

In the past several decades, an abundance of data related to the signaling events that trigger and maintain PCa have been collected. An increasing knowledge of the interconnections (crosstalks) of different signaling cascades, that ultimately promote the advance of PCa, is of seminal importance for the development of specific drugs which might promote the blockage and/or induction of specific molecules that could lead to the control of tumor progression. In fact, several drugs are currently in clinical trials or being tested in animal models, most of them acting as specific inhibitors of deregulated signaling pathways, such as those described in this review. Nevertheless, a more detailed and interactive panel of the external factors capable of inducing the deregulation(s) observed in the PCa microenvironment is still missing. Thus, it is crucial to pursue a more complete understanding of the cascade-dependent signals that lie behind PCa induction, to consequently lead to the development of fully functional strategies against PCa. This will also advance our knowledge towards more efficient screenings of PCa predisposition, which will certainly lead to increased prevention schemes and early treatments against this malady.

Authors' Contribution

H. B. da Silva and E. P. Amaral contributed equally to this paper.


The authors thank the Department of Genetics and Evolutionary Biology from the Institute of Biosciences (IB) of the University of Sao Paulo (USP, Sao Paulo, Brazil) and, particularly, Drs. Luis Eduardo Soares Netto and Regina Celia Mingroni Netto (IB-USP) for the academic support and opportunity to write this review. R. G. Correa is supported by grants from NIH.


[1] M. Verras and Z. Sun, "Roles and regulation of Wnt signaling and [beta]-catenin in prostate cancer," Cancer Letters, vol. 237, no. 1, pp. 22-32, 2006.

[2] J. K. Mullins and S. Loeb, "Environmental exposures and prostate cancer," Urologic Oncology, vol. 30, pp. 216-219, 2012.

[3] R. Siegel, C. DeSantis, K. Virgo et al., "Cancer treatment and survivorship statistics, 2012," CA: A Cancer Journal for Clinicians, vol. 62, pp. 220-241, 2012.

[4] F. C. Maluf, O. Smaletz, and D. Herchenhorn, "Castration-resistant prostate cancer: systemic therapy in 2012," Clinics, vol. 67, pp. 389-394, 2012.

[5] M. M. Center, A. Jemal, J. Lortet-Tieulent et al., "International variation in prostate cancer incidence and mortality rates," European Urology, vol. 61, pp. 1079-1092, 2012.

[6] G. Arcangeli, B. Saracino, S. Gomellini et al., "A Prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer," International Journal of Radiation Oncology Biology Physics, vol. 78, no. 1, pp. 11-18, 2010.

[7] H. G. Sim and C. W. S. Cheng, "Changing demography of prostate cancer in Asia," European Journal of Cancer, vol. 41, no. 6, pp. 834-845, 2005.

[8] S. H. Reuben, "Reducing environmental cancer risk: what we can do now," The President's Cancer Panel, pp. 1-240, 2010.

[9] M. F. Leitzmann and S. Rohrmann, "Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates," Clinical Epidemiology, vol. 4, pp. 1-11, 2012.

[10] B. G. Timms, "Prostate development: a historical perspective," Differentiation, vol. 76, no. 6, pp. 565-577, 2008.

[11] A. R. Kristal, K. B. Arnold, M. L. Neuhouser et al., "Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial," American Journal of Epidemiology, vol. 172, no. 5, pp. 566-577, 2010.

[12] L. J. Su, L. Arab, S. E. Steck et al., "Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study," Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 5, pp. 844-853, 2011.

[13] S. Koifman and R. J. Koifman, "Environment and cancer in Brazil: an overview from a public health perspective," Mutation Research, vol. 544, no. 2-3, pp. 305-311, 2003.

[14] R. Sichieri, J. E. Everhart, and G. A. Mendonca, "Diet and mortality from common cancers in Brazil: an ecological study," Cadernos de Saude Publica, vol. 12, pp. 53-59,1996.

[15] P. Cocco, "On the rumors about the silent spring. Review of the scientific evidence linking occupational and environmental pesticide exposure to endocrine disruption health effects," Cadernos de Saude Publica, vol. 18, no. 2, pp. 379-402, 2002.

[16] H. J. van der Rhee, E. de Vries, and J. W. W. Coebergh, "Does sunlight prevent cancer? A systematic review," European Journal of Cancer, vol. 42, no. 14, pp. 2222-2232, 2006.

[17] S. J. Freedland, W. B. Isaacs, E. A. Platz et al., "Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study," Journal of Clinical Oncology, vol. 23, no. 30, pp. 7546-7554, 2005.

[18] H. T. Lynch and J. F. Lynch, "The Lynch syndrome: melding natural history and molecular genetics to genetic counseling and cancer control," Cancer Control, vol. 3, no. 1, pp. 13-19,1996.

[19] J. K. Jin, F. Dayyani, and G. E. Gallick, "Steps in prostate cancer progression that lead to bone metastasis," International Journal of Cancer, vol. 128, no. 11, pp. 2545-2561, 2011.

[20] P. E. Lonergan and D. J. Tindall, "Androgen receptor signaling in prostate cancer development and progression," Journal of Carcinogenesis, vol. 10, article 20, 2011.

[21] S. A. Boorjian, J. A. Eastham, M. Graefen et al., "A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes," European Urology, vol. 61, pp. 664-675, 2012.

[22] Z. Culig, A. Hobisch, M. V. Cronauer et al., "Androgen receptor activation in prostatic tumor cell lines by insulin- like growth factor-I, keratinocyte growth factor, and epidermal growth factor," Cancer Research, vol. 54, no. 20, pp. 5474-5478,1994.

[23] A. Wolk, C. S. Mantzoros, S. O. Andersson et al., "Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study," Journal of the National Cancer Institute, vol. 90, no. 12, pp. 911-915,1998.

[24] D. Gioeli, S. B. Ficarro, J. J. Kwiek et al., "Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites," Journal of Biological Chemistry, vol. 277, no. 32, pp. 29304-29314, 2002.

[25] Z. Guo, B. Dai, T. Jiang et al., "Regulation of androgen receptor activity by tyrosine phosphorylation," Cancer Cell, vol. 10, no. 4, pp. 309-319, 2006.

[26] E. Hernes, Fossa, A. Berner, B. Otnes, and J. M. Nesland, "Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence," British Journal of Cancer, vol. 90, no. 2, pp. 449-454, 2004.

[27] S. M. Green, E. A. Mostaghel, and P. S. Nelson, "Androgen action and metabolism in prostate cancer," Molecular and Cellular Endocrinology, vol. 360, pp. 3-13, 2012.

[28] S. Q. Yu, K. P. Lai, S. J. Xia, H. C. Chang, C. Chang, and S. Yeh, "The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer," Asian Journal of Andrology, vol. 11, no. 1, pp. 39-48, 2009.

[29] C. Glampietri, S. Petrungaro, F. Padula et al., "Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-[alpha]lpha-dependent apoptosis," Apoptosis, vol. 17, no. 11, pp. 1210-1222, 2012.

[30] X. Huang, F. Yuan, M. Liang et al., "M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer," PLoS ONE, vol. 7, Article ID e41632, 2012.

[31] A. Vajda, L. Marignol, C. Barrett et al., "Gene expression analysis in prostate cancer: the importance of the endogenous control," Prostate, vol. 73, pp. 382-390, 2012.

[32] C. E. Lin, S. U. Chen, C. C. Lin et al., "Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells," PLoS ONE, vol. 7, Article ID e41096, 2012.

[33] P. Saraon, N. Musrap, D. Cretu et al., "Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer," Journal of Biological Chemistry, vol. 287, pp. 34019-34031, 2012.

[34] B. S. Carver, C. Chapinski, J. Wongvipat et al., "Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer," Cancer Cell, vol. 19, no. 5, pp. 575-586, 2011.

[35] J. A. Ewald, J. A. Desotelle, D. R. Church et al., "Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo," Prostate, vol. 73, pp. 337-345,2012.

[36] P. J. Maxwell, J. Coulter, S. M. Walker et al., "Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma," European Urology, 2012.

[37] R. S. Jackson II, W. Placzek, A. Fernandez et al., "Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer," Neoplasia, vol. 14, pp. 656-665, 2012.

[38] H. Wang, Y. Xu, Z. Fang, S. Chen, S. P. Balk, and X. Yuan, "Doxycycline regulated induction of AKT in murine prostate drives proliferation independently of p27 cyclin dependent kinase inhibitor downregulation," PLoS ONE, vol. 7, Article ID e41330, 2012.

[39] M. A. Reynolds, "Molecular alterations in prostate cancer," Cancer Letters, vol. 271, no. 1, pp. 13-24, 2008.

[40] M. E. Grossmann, H. Huang, and D. J. Tindall, "Androgen receptor signaling in androgen-refractory prostate cancer," Journal of the National Cancer Institute, vol. 93, no. 22, pp. 1687-1697, 2001.

[41] S. C. Chan, Y. Li, and S. M. Dehm, "Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal," Journal of Biological Chemistry, vol. 287, pp. 19736-19749, 2012.

[42] G. Castoria, L. D'Amato, A. Ciociola et al., "Androgen-induced cell migration: role of androgen receptor/filamin A association," PLoS ONE, vol. 6, Article ID e17218, 2012.

[43] K. K. Waltering, A. Urbanucci, and T. Visakorpi, "Androgen receptor (AR) aberrations in castration-resistant prostate cancer," Molecular and Cellular Endocrinology, vol. 360, pp. 38-43, 2012.

[44] H. Wang, C. Zhang, A. Rorick et al., "CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability," Cancer Research, vol. 71, no. 14, pp. 4866-4876, 2011.

[45] A. Urbanucci, B. Sahu, J. Seppala et al., "Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer," Oncogene, vol. 31, pp. 2153-2163, 2012.

[46] M. Shiota, A. Yokomizo, and S. Naito, "Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target," Journal of Molecular Endocrinology, vol. 47, no. 1, pp. R25-R41, 2011.

[47] M. Shiota, A. Yokomizo, and S. Naito, "Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer," Free Radical Biology and Medicine, vol. 51, pp. 1320-1328, 2011.

[48] Y. Zuo and J. K. Cheng, "Small ubiquitin-like modifier protein-specific protease 1 and prostate cancer," Asian Journal of Andrology, vol. 11, no. 1, pp. 36-38, 2009.

[49] T. Bawa-Khalfe, J. Cheng, Z. Wang, and E. T. H. Yeh, "Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells," Journal of Biological Chemistry, vol. 282, no. 52, pp. 37341-37349, 2007

[50] N. D. Perkins, "Integrating cell-signalling pathways with NF-kappaB and IKK function," Nature Reviews Molecular Cell Biology, vol. 8, pp. 49-62, 2007

[51] C. Cai, F. N. Jiang, Y. X. Liang et al., "Classical and alternative nuclear factor-kappaB pathways: a comparison among normal prostate, benign prostate hyperplasia and prostate cancer," Pathology and Oncology Research, vol. 17, pp. 873-878, 2011.

[52] V. Tergaonkar, "NF[kappa]B pathway: a good signaling paradigm and therapeutic target," International Journal of Biochemistry and Cell Biology, vol. 38, no. 10, pp. 1647-1653, 2006.

[53] B. Razani, A. D. Reichardt, and G. Cheng, "Non-canonical NF-kappaB signaling activation and regulation: principles and perspectives," Immunological Reviews, vol. 244, pp. 44-54, 2011.

[54] R. C. Rickert, J. Jellusova, and A. V. Miletic, "Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease," Immunological Reviews, vol. 244, pp. 115-133, 2011.

[55] L. Gu, A. Dagvadorj, J. Lutz et al., "Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth," American Journal of Pathology, vol. 176, no. 4, pp. 1959-1972, 2010.

[56] J. Chen, K. V. Giridhar, L. Zhang, S. Xu, and Q. Jane Wang, "A protein kinase C/protein kinase D pathway protects LNCaP prostate cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF-[kappa]B activities," Carcinogenesis, vol. 32, no. 8, pp. 1198-1206, 2011.

[57] A. Hsu, R. S. Bruno, C. V. Lohr et al., "Dietary soy and tea mitigate chronic inflammation and prostate cancer via NF[kappa]B pathway in the Noble rat model," Journal of Nutritional Biochemistry, vol. 22, no. 5, pp. 502-510, 2011.

[58] R. Benelli, R. Vene, M. Ciarlo, S. Carlone, O. Barbieri, and N. Ferrari, "The AKT/NF-kappaB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration," Biochemical Pharmacology, vol. 83, pp. 1634-1642, 2012.

[59] G. Jain, C. Voogdt, A. Tobias et al., "IkappaB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines," Neoplasia, vol. 14, pp. 178-189, 2012.

[60] Y. Fang, H. Sun, J. Zhai et al., "Antitumor activity of NF-[kappa]B decoy oligodeoxynucleotides in a prostate cancer cell line," Asian Pacific Journal of Cancer Prevention, vol. 12, pp. 2721-2726, 2012.

[61] W. Xiao, D. R. Hodge, L. Wang, X. Yang, X. Zhang, and W L. Farrar, "Co-operative functions between nuclear factors NF[kappa]B and CCAT/enhancer-binding protein-[beta] (C/EBP-[beta]) regulate the IL-6 promoter in autocrine human prostate cancer cells," Prostate, vol. 61, no. 4, pp. 354-370, 2004.

[62] S. Shukla, G. T. MacLennan, P. Fu et al., "Nuclear factor-[kappa]B/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression," Neoplasia, vol. 6, no. 4, pp. 390-400, 2004.

[63] C. D. Chen and C. L. Sawyers, "NF-[kappa]B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer," Molecular and Cellular Biology, vol. 22, no. 8, pp. 2862-2870, 2002.

[64] M. Paz De Miguel, M. Royuela, F. R. Bethencourt, L. Santamaria, B. Fraile, and R. Paniagua, "Immunoexpression of tumour necrosis factor-[alpha] and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostrate," Cytokine, vol. 12, no. 5, pp. 535-538, 2000.

[65] G. Rodriguez-Berriguete, B. Fraile, R. Paniagua, P. Aller, and M. Royuela, "Expression of NF-kappaB-related proteins and their modulation during TNF-[alpha]lpha-provoked apoptosis in prostate cancer cells," Prostate, vol. 72, pp. 40-50, 2012.

[66] Y. Bouraoui, M. Ricote, I. Garcia-Tunon et al., "Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer," Cancer Detection and Prevention, vol. 32, no. 1, pp. 23-32, 2008.

[67] S. Srinivasan, R. Kumar, S. Koduru, A. Chandramouli, and C. Damodaran, "Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer," Apoptosis, vol. 15, no. 2, pp. 153-161, 2010.

[68] G. Rodriguez-Berriguete, B. Fraile, F. R. de Bethencourt et al., "Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate," BMC Cancer, vol. 10, article 18, 2010.

[69] C. D. Chen, D. S. Welsbie, C. Tran et al., "Molecular determinants of resistance to antiandrogen therapy," Nature Medicine, vol. 10, no. 1, pp. 33-39, 2004.

[70] L. Zhang, S. Altuwaijri, F. Deng et al., "NF-[kappa]B regulates androgen receptor expression and prostate cancer growth," American Journal of Pathology, vol. 175, no. 2, pp. 489-499, 2009.

[71] G. Jain, M. V. Cronauer, M. Schrader, P. Moller, and R. B. Marienfeld, "NF-kappaB signaling in prostate cancer: a promising therapeutic target?" World Journal of Urology, vol. 30, pp. 303-310, 2012.

[72] S. I. Grivennikov and M. Karin, "Dangerous liaisons: STAT3 and NF-[kappa]B collaboration and crosstalk in cancer," Cytokine and Growth Factor Reviews, vol. 21, no. 1, pp. 11-19, 2010.

[73] G. Schneider and O. H. Kramer, "NFkappaB/p53 crosstalka promising new therapeutic target," Biochimica et Biophysica Acta, vol. 1815, pp. 90-103, 2011.

[74] A. Oeckinghaus, M. S. Hayden, and S. Ghosh, "Crosstalk in NF-kappaB signaling pathways," Nature Immunology, vol. 12, pp. 695-708, 2011.

[75] I. Vivanco and C. L. Sawyers, "The phosphatidylinositol 3-kinase-AKT pathway in human cancer," Nature Reviews Cancer, vol. 2, no. 7, pp. 489-501, 2002.

[76] A. G. Bader, S. Kang, L. Zhao, and P. K. Vogt, "Oncogenic PI3K deregulates transcription and translation," Nature Reviews Cancer, vol. 5, no. 12, pp. 921-929, 2005.

[77] J. A. Engelman, J. Luo, and L. C. Cantley, "The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism," Nature Reviews Genetics, vol. 7, no. 8, pp. 606-619, 2006.

[78] D. A. Guertin and D. M. Sabatini, "Defining the role of mTOR in cancer," Cancer Cell, vol. 12, no. 1, pp. 9-22, 2007

[79] L. Bozulic and B. A. Hemmings, "PIKKing on PKB: regulation of PKB activity by phosphorylation," Current Opinion in Cell Biology, vol. 21, no. 2, pp. 256-261, 2009.

[80] M. P. Scheid and J. R. Woodgett, "PKB/AKT: functional insights from genetic models," Nature Reviews Molecular Cell Biology, vol. 2, no. 10, pp. 760-768, 2001.

[81] B. D. Manning and L. C. Cantley, "AKT/PKB signaling: navigating downstream," Cell, vol. 129, no. 7, pp. 1261-1274, 2007

[82] L. C. Cantley, "The phosphoinositide 3-kinase pathway," Science, vol. 296, no. 5573, pp. 1655-1657, 2002.

[83] T. M. Morgan, T. D. Koreckij, and E. Corey, "Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway," Current Cancer Drug Targets, vol. 9, no. 2,pp. 237-249, 2009.

[84] A. Di Cristofano, B. Pesce, C. Cordon-Cardo, and P. P. Pandolfi, "Pten is essential for embryonic development and tumour suppression," Nature Genetics, vol. 19, no. 4, pp. 348-355, 1998.

[85] J. L. Boormans, H. Korsten, A. C. J. Ziel-Van Der Made, G. J. L. H. Van Leenders, P. C. M. S. Verhagen, and J. Trapman, "E17K substitution in AKT1 in prostate cancer," British Journal of Cancer, vol. 102, no. 10, pp. 1491-1494, 2010.

[86] L. C. Trotman, M. Niki, Z. A. Dotan et al., "Pten dose dictates cancer progression in the prostate," PLoS Biology, vol. 1, no. 3, article E59, 2003.

[87] Z. Chen, L. C. Trotman, D. Shaffer et al., "Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis," Nature, vol. 436, no. 7051, pp. 725-730, 2005.

[88] A. Di Cristofano, M. De Acetis, A. Koff, C. Cordon-Cardo, and P. P Pandolfi, "Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse," Nature Genetics, vol. 27, no. 2, pp. 222-224, 2001.

[89] L. Poliseno, L. Salmena, L. Riccardi et al., "Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation," Science Signaling, vol. 3, no. 117, article ra29, 2010.

[90] M. S. Song, L. Salmena, A. Carracedo et al., "The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network," Nature, vol. 455, no. 7214, pp. 813-817, 2008.

[91] M. S. Song, L. Salmena, and P. P. Pandolfi, "The functions and regulation of the PTEN tumour suppressor," Nature Reviews Molecular Cell Biology, vol. 13, pp. 283-296, 2012.

[92] A. Almasan and A. Ashkenazi, "Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy," Cytokine and Growth Factor Reviews, vol. 14, no. 3-4, pp. 337-348, 2003.

[93] J. Xu, J. Y. Zhou, W. Z. Wei, and G. S. Wu, "Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells," PLoS ONE, vol. 5, no. 4, Article ID e10226, 2010.

[94] N. Tzenaki, M. Andreou, K. Stratigi et al., "High levels of p110delta PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110delta inhibitors through PTEN activation," FASEB Journal, vol. 26, pp. 2498-2508, 2012.

[95] S. H. Lee, G. Poulogiannis, S. Pyne et al., "A constitutively activated form of the p110[beta] isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 24, pp. 11002-11007, 2010.

[96] B. Cinar, P. K. Fang, M. Lutchman et al., "The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1," EMBO Journal, vol. 26, no. 21, pp. 4523-4534, 2007.

[97] B. Cinar, F. K. Collak, D. Lopez et al., "MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling," Cancer Research, vol. 71, no. 12, pp. 4303-4313, 2011.

[98] Z. Yuan, D. Kim, S. Shu et al., "Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic signaling through phosphorylation of threonine 120," Journal of Biological Chemistry, vol. 285, no. 6, pp. 3815-3824, 2010.

[99] K. Mahajan, D. Coppola, S. Challa et al., "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation," PloS ONE, vol. 5, no. 3, article e9646, 2010.

[100] K. Nacerddine, J. B. Beaudry, V. Ginjala et al., "Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer," Journal of Clinical Investigation, vol. 122, pp. 1920-1932, 2012.

[101] M. Gao, R. Patel, I. Ahmad et al., "SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis," EMBO Molecular Medicine, vol. 4, pp. 776-790, 2012.

[102] V. M. Adhami, I. A. Siddiqui, S. Sarfaraz et al., "Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on Thestage of the disease," Clinical Cancer Research, vol. 15, no. 6, pp. 1947-1953, 2009.

[103] V. M. Adhami, I. A. Siddiqui, N. Ahmad, S. Gupta, and H. Mukhtar, "Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer," Cancer Research,vol. 64, no. 23, pp. 8715-8722, 2004.

[104] H. J. Kung and C. P. Evans, "Oncogenic activation of androgen receptor," Urologic Oncology, vol. 27, no. 1, pp. 48-52, 2009.

[105] N. J. Clegg, S. S. Couto, J. Wongvipat et al., "MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors," PLoS ONE, vol. 6, no. 3, Article ID e17449, 2011.

[106] D. N. Gunadharini, P. Elumalai, R. Arunkumar, K. Senthilkumar, and J. Arunakaran, "Induction of apoptosis and inhibition of PI3K/Akt pathway in PC-3 and LNCaP prostate cancer cells by ethanolic neem leaf extract," Journal of Ethnopharmacology, vol. 134, no. 3, pp. 644-650, 2011.

[107] K. R. Park, D. Nam, H. M. Yun et al., "beta-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation," Cancer Letters, vol. 312, pp. 178-188, 2011.

[108] V. M. Adhami, D. N. Syed, N. Khan, and H. Mukhtar, "Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management," Biochemical Pharmacology, vol. 84, pp. 1277-1281, 2012.

[109] Z. Wang, Y. Zhang, S. Banerjee, Y. Li, and F. H. Sarkar, "Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells," Cancer, vol. 106, no. 11, pp. 2503-2513, 2006.

[110] M. J. Ryu, M. Cho, J. Y. Song et al., "Natural derivatives of curcumin attenuate the Wnt/[beta]-catenin pathway through downregulation of the transcriptional coactivator p300," Biochemical and Biophysical Research Communications, vol. 377, no. 4, pp. 1304-1308, 2008.

[111] S. Yu, G. Shen, O. K. Tin, J. H. Kim, and A. N. T. Kong, "Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism," Molecular Cancer Therapeutics, vol. 7, no. 9, pp. 2609-2620, 2008.

[112] A. Slusarz, N. S. Shenouda, M. S. Sakla et al., "Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer," Cancer Research, vol. 70, no. 8, pp. 3382-3390, 2010.

[113] O. W. Rokhlin, N. V. Guseva, A. F. Taghiyev, R. A. Glover, and M. B. Cohen, "KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer," Cancer Biology and Therapy, vol. 9, no. 3, pp. 224-235, 2010.

[114] J. J. Wallin, K. A. Edgar, J. Guan et al., "GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway," Molecular Cancer Therapeutics, vol. 10, pp. 2426-2436, 2011.

[115] S. M. Manohar, A. A. Padgaonkar, A. J. Badhwar et al., "A novel inhibitor of hypoxia-inducible factor-1alpha P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells," BMC Cancer, vol. 11, article 338, 2011.

[116] L. Lu, D. Tang, L. Wang et al., "Gambogic acid inhibits TNF-[alpha]lpha-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-kappaB signaling pathways," Acta Pharmacologica Sinica, vol. 33, pp. 531-541, 2012.

[117] S. L. Burgio, F. Fabbri, I. J. Seymour, W. Zoli, D. Amadori, and U. De Giorgi, "Perspectives on mTOR inhibitors for castration-refractory prostate cancer," Current Cancer Drug Targets, vol. 12, pp. 940-949, 2012.

[118] E. C. Nelson, C. P. Evans, P. C. Mack, R. W. Devere-White, and P. N. Lara Jr., "Inhibition of Akt pathways in the treatment of prostate cancer," Prostate Cancer and Prostatic Diseases, vol. 10, no. 4, pp. 331-339, 2007.

[119] C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis, "Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway," Clinical Cancer Research, vol. 12, no. 3, pp. 679-689,2006.

[120] S. B. Kondapaka, S. S. Singh, G. P. Dasmahapatra, E. A. Sausville, and K. K. Roy, "Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation," Molecular Cancer Therapeutics, vol. 2, no. 11, pp. 1093-1103, 2003.

[121] C. G. Tepper, R. L. Vinall, C. B. Wee et al., "GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms," Prostate, vol. 67, no. 5, pp. 521-535, 2007

[122] P. B. Makhov, K. Golovine, A. Kutikov et al., "Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells," Molecular Cancer Therapeutics, vol. 11, pp. 1510-1517, 2012.

[123] H. Kiu and S. E. Nicholson, "Biology and significance of the JAK/STAT signalling pathways," Growth Factors, vol. 30, pp. 88-106, 2012.

[124] D. A. Harrison, "The Jak/STAT pathway," Cold Spring Harbor Perspectives in Biology, vol. 4, 2012.

[125] W. X. Li, "Canonical and non-canonical JAK-STAT signaling," Trends in Cell Biology, vol. 18, no. 11, pp. 545-551, 2008.

[126] D. Hebenstreit, J. Horejs-Hoeck, and A. Duschl, "JAK/STAT-dependent gene regulation by cytokines," Drug News and Perspectives, vol. 18, no. 4, pp. 243-249, 2005.

[127] J. J. O'Shea, H. Park, M. Pesu, D. Borie, and P. Changelian, "New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway," Current Opinion in Rheumatology, vol. 17, no. 3, pp. 305-311, 2005.

[128] P. Igaz, S. Toth, and A. Falus, "Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice," Inflammation Research, vol. 50, no. 9, pp. 435-441, 2001.

[129] J. J. O'Shea, M. Gadina, and R. D. Schreiber, "Cytokine signaling in 2002: new surprises in the Jak/Stat pathway," Cell, vol. 109, no. 2, pp. S121-S131, 2002.

[130] J. E. Darnell Jr., "STATs and gene regulation," Science, vol. 277, no. 5332, pp. 1630-1635,1997

[131] J. N. Ihle, W. Thierfelder, S. Teglund et al., "Signaling by the cytokine receptor superfamily," Annals of the New York Academy of Sciences, vol. 865, pp. 1-9,1998.

[132] K. Shuai, C. M. Horvath, L. H. T. Huang, S. A. Qureshi, D. Cowburn, and J. E. Darnell Jr., "Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions," Cell, vol. 76, no. 5, pp. 821-828, 1994.

[133] S. Gupta, T. Barrett, A. J. Whitmarsh et al., "Selective interaction of JNK protein kinase isoforms with transcription factors," EMBO Journal, vol. 15, no. 11, pp. 2760-2770,1996.

[134] K. Mowen and M. David, "Role of the STAT1-SH2 domain and STAT2 in the activation and nuclear translocation of STAT1," Journal of Biological Chemistry, vol. 273, no. 46, pp. 30073-30076, 1998.

[135] J. S. Rawlings, K. M. Rosler, and D. A. Harrison, "The JAK/STAT signaling pathway," Journal of Cell Science, vol. 117, no. 8, pp. 1281-1283, 2004.

[136] J. Bromberg, "Stat proteins and oncogenesis," Journal of Clinical Investigation, vol. 109, no. 9, pp. 1139-1142, 2002.

[137] H. Yu and R. Jove, "The stats of cancer--new molecular targets come of age," Nature Reviews Cancer, vol. 4, no. 2, pp. 97-105, 2004.

[138] A. Tutt and A. Ashworth, "The relationship between the roles of BRCA genes in DNA repair and cancer predisposition," Trends in Molecular Medicine, vol. 8, no. 12, pp. 571-576, 2002.

[139] H. Wallerand, G. Robert, J. C. Bernhard, A. Ravaud, and J. J. Patard, "Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer," Archivos Espanoles de Urologia, vol. 63, no. 9, pp. 773-787, 2010.

[140] E. M. Kwon, S. K. Holt, R. Fu et al., "Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk," Cancer Epidemiology, vol. 36, pp. 347-353, 2012.

[141] D. A. Frank, "STAT3 as a central mediator of neoplastic cellular transformation," Cancer Letters, vol. 251, no. 2, pp. 199-210, 2007.

[142] B. Gao, X. Shen, G. Kunos et al., "Constitutive activation of JAKSTAT3 signaling by BRCA1 in human prostate cancer cells," FEBS Letters, vol. 488, no. 3, pp. 179-184, 2001.

[143] A. R. Venkitaraman, "Cancer susceptibility and the functions of BRCA1 and BRCA2," Cell, vol. 108, no. 2, pp. 171-182, 2002.

[144] E. A. Ostrander and M. S. Udler, "The role of the BRCA2 gene in susceptibility to prostate cancer revisited," Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 8, pp. 1843-1848, 2008.

[145] S. Panchal, O. Shachar, F. O'Malley et al., "Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer," Nature Reviews Clinical Oncology, vol. 6, no. 10, pp. 604-607, 2009.

[146] N. Rahman and M. R. Stratton, "The genetics of breast cancer susceptibility," Annual Review of Genetics, vol. 32, pp. 95-121, 1998.

[147] P. Kerr and A. Ashworth, "New complexities for BRCA1 and BRCA2," Current Biology, vol. 11, no. 16, pp. R668-R676, 2001.

[148] M. Sakaguchi, M. Oka, T. Iwasaki, Y. Fukami, and C. Nishigori, "Role and regulation of STAT3 phosphorylation at Ser727 in melanocytes and melanoma cells," Journal of Investigative Dermatology, vol. 132, pp. 1877-1885, 2012.

[149] J. Cao, P. Kozarekar, M. Pavlaki, C. Chiarelli, W. F. Bahou, and S. Zucker, "Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration," Journal of Biological Chemistry, vol. 279, no. 14, pp. 14129-14139, 2004.

[150] V. I. Romanov, T. Whyard, H. L. Adler, W. C. Waltzer, and S. Zucker, "Prostate cancer cell adhesion to bone marrow endothelium: the role of prostate-specific antigen," Cancer Research, vol. 64, no. 6, pp. 2083-2089, 2004.

[151] H. L. Nguyen, S. Zucker, K. Zarrabi, P. Kadam, C. Schmidt, and J. Cao, "Oxidative stress and prostate cancer progression are elicited by membrane-type 1 matrix metalloproteinase," Molecular Cancer Research, vol. 9, pp. 1305-1318, 2011.

[152] D. Kesanakurti, C. Chetty, D. H. Dinh, M. Gujrati, and J. S. Rao, "Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with alpha5beta1 integrin in glioma," Oncogene, vol. 32, pp. 327-340, 2012.

[153] R. Dhir, Z. Ni, W. Lou, F. DeMiguel, J. R. Grandis, and A. C. Gao, "Stat3 activation in prostatic carcinomas," Prostate, vol. 51, no. 4, pp. 241-246, 2002.

[154] X. Liu, Z. He, C. H. Li, G. Huang, C. Ding, and H. Liu, "Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer," Pathology and Oncology Research, vol. 18, pp. 17-23, 2012.

[155] R. Aalinkeel, Z. Hu, B. B. Nair et al., "Genomic analysis highlights the role of the JAK-STAT signaling in the antiproliferative effects of dietary--flavonoid "ashwagandha" in prostate cancer cells," Evidence-Based Complementary and Alternative Medicine, vol. 7, no. 2, pp. 177-187, 2010.

[156] K. Ishihara and T. Hirano, "IL-6 in autoimmune disease and chronic inflammatory proliferative disease," Cytokine and Growth Factor Reviews, vol. 13, no. 4-5, pp. 357-368, 2002.

[157] T. Kishimoto, "Interleukin-6: from basic science to medicine--40 years in immunology," Annual Review of Immunology, vol. 23, pp. 1-21, 2005.

[158] A. Hobisch, H. Rogatsch, A. Hittmair et al., "Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue," Journal of Pathology, vol. 191, pp. 239-244, 2000.

[159] P. C. Smith, A. Hobisch, D. L. Lin, Z. Culig, and E. T. Keller, "Interleukin-6 and prostate cancer progression," Cytokine and Growth Factor Reviews, vol. 12, no. 1, pp. 33-40, 2001.

[160] J. R. Stark, H. Li, P. Kraft et al., "Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality," International Journal of Cancer, vol. 124, no. 11, pp. 2683-2689, 2009.

[161] J. Karkera, H. Steiner, W. Li et al., "The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study," Prostate, vol. 71, pp. 1455-1465, 2011.

[162] D. A. Twillie, M. A. Eisenberger, M. A. Carducci, W. S. Hseih, W. Y. Kim, and J. W. Simons, "Interleukin-6: a candidate mediator of human prostate cancer morbidity," Urology, vol. 45, no. 3, pp. 542-549, 1995.

[163] M. Okamoto, C. Lee, and R. Oyasu, "Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro," Cancer Research, vol. 57, no. 1, pp. 141-146,1997.

[164] I. T. Cavarretta, H. Neuwirt, G. Untergasser et al., "The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1," Oncogene, vol. 26, no. 20, pp. 2822-2832, 2007.

[165] T. D. Chung, J. J. Yu, M. T. Spiotto, M. Bartkowski, and J. W. Simons, "Characterization of the role of IL-6 in the progression of prostate cancer," Prostate, vol. 38, pp. 199-207,1999.

[166] W. Lou, Z. Ni, K. Dyer, D. J. Tweardy, and A. C. Gao, "Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway," Prostate, vol. 42, pp. 239-242, 2000.

[167] I. Sakai, H. Miyake, T. Terakawa, and M. Fujisawa, "Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model," Cancer Science, vol. 102, no. 4, pp. 769-775, 2011.

[168] L. R. Dearth and J. DeWille, "An AU-rich element in the 31 untranslated region of the C/EBP[delta] mRNA is important for protein binding during G0 growth arrest," Biochemical and Biophysical Research Communications, vol. 304, no. 2, pp. 344-350, 2003.

[169] L. R. Dearth and J. DeWille, "Posttranscriptional andposttranslational regulation of C/EBP[delta] in Go growth-arrested mammary epithelial cells," Journal of Biological Chemistry, vol. 278, no. 13, pp. 11246-11255, 2003.

[170] D. P. Ramji and P. Foka, "CCAAT/enhancer-binding proteins: structure, function and regulation," Biochemical Journal, vol. 365, no. 3, pp. 561-575, 2002.

[171] D. C. Sanford and J. W. DeWille, "C/EBP[delta] is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells," Prostate, vol. 63, no. 2, pp. 143-154, 2005.

[172] E. LaTulippe, J. Satagopan, A. Smith et al., "Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease," Cancer Research, vol. 62, no. 15, pp. 4499-4506, 2002.

[173] B. Binetruy, L. Heasley, F. Bost, L. Caron, and M. Aouadi, "Concise review: regulation of embryonic stem cell lineage commitment by mitogen-activated protein kinases," Stem Cells, vol. 25, no. 5, pp. 1090-1095, 2007

[174] A. S. Dhillon, S. Hagan, O. Rath, and W. Kolch, "MAP kinase signalling pathways in cancer," Oncogene, vol. 26, no. 22, pp. 3279-3290, 2007

[175] E. F. Wagner and A. R. Nebreda, "Signal integration by JNK and p38 MAPK pathways in cancer development," Nature Reviews Cancer, vol. 9, no. 8, pp. 537-549, 2009.

[176] Y. T. Ip and R. J. Davis, "Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development," Current Opinion in Cell Biology, vol. 10, no. 2, pp. 205-219,1998.

[177] T. H. Holmstrom, I. Schmitz, T. S. Soderstrom et al., "MAPK/ ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly," EMBO Journal, vol. 19, no. 20, pp. 5418-5428, 2000.

[178] K. Gupta, S. Kshirsagar, W. Li et al., "VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling," Experimental Cell Research, vol. 247, no. 2, pp. 495-504,1999.

[179] A. Ogata, D. Chauhan, G. Teoh et al., "IL-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade," Journal of Immunology, vol. 159, no. 5, pp. 2212-2221, 1997.

[180] V. Flati, E. Pasini, G. DAntona, S. Speca, E. Toniato, and S. Martinotti, "Intracellular mechanisms of metabolism regulation: the role of signaling via the mammalian target of rapamycin pathway and other routes," American Journal of Cardiology, vol. 101, no. 11, pp. S16-S21, 2008.

[181] S. Davis, P. Vanhoutte, C. Pages, J. Caboche, and S. Laroche, "The MAPK/ERK cascade targets both Elk-1 and cAMP response element- binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo," Journal of Neuroscience, vol. 20, no. 12, pp. 4563-4572, 2000.

[182] J. Guicheux, J. Lemonnier, C. Ghayor, A. Suzuki, G. Palmer, and J. Caverzasio, "Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation," Journal of Bone and Mineral Research, vol. 18, no. 11, pp. 2060-2068, 2003.

[183] C. Huang, K. Jacobson, and M. D. Schaller, "MAP kinases and cell migration," Journal of Cell Science, vol. 117, no. 20, pp. 4619-4628, 2004.

[184] M. A. Lemmon and J. Schlessinger, "Cell signaling by receptor tyrosine kinases," Cell, vol. 141, no. 7, pp. 1117-1134, 2010.

[185] L. A. Fecher, R. K. Amaravadi, and K. T. Flaherty, "The MAPK pathway in melanoma," Current Opinion in Oncology, vol. 20, no. 2, pp. 183-189, 2008.

[186] Y. Fleming, C. G. Armstrong, N. Morrice, A. Paterson, M. Goedert, and P. Cohen, "Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/ JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7," Biochemical Journal, vol. 352, no. 1, pp. 145-154, 2000.

[187] W. Haeusgen, T. Herdegen, and V. Waetzig, "The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7," European Journal of Cell Biology, vol. 90, no. 6-7, pp. 536-544, 2011.

[188] W. Xin, K. J. Yun, F. Ricci et al., "MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course," Clinical Cancer Research, vol. 10, no. 24, pp. 8516-8520, 2004.

[189] S. D. Yamada, J. A. Hickson, Y. Hrobowski et al., "Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma," Cancer Research, vol. 62, no. 22, pp. 6717-6723, 2002.

[190] R. Chiu, W. J. Boyle, J. Meek, T. Smeal, T. Hunter, and M. Karin, "The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes," Cell, vol. 54, no. 4, pp. 541-552, 1988.

[191] C. Jonat, H. J. Rahmsdorf, K. K. Park et al., "Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone," Cell, vol. 62, no. 6, pp. 1189-1204, 1990.

[192] C. W. Kinkade, M. Castillo-Martin, A. Puzio-Kuter et al., "Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model," Journal of Clinical Investigation, vol. 118, no. 9, pp. 3051-3064, 2008.

[193] M. T. Abreu-Martin, A. Chari, A. A. Palladino, N. A. Craft, and C. L. Sawyers, "Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer," Molecular and Cellular Biology, vol. 19, no. 7, pp. 5143-5154,1999.

[194] D. Gioeli, J. W. Mandell, G. R. Petroni, H. F. Frierson, and M. J. Weber, "Activation of mitogen-activated protein kinase associated with prostate cancer progression," Cancer Research, vol. 59, no. 2, pp. 279-284,1999.

[195] A. M. Carey, R. Pramanik, L. J. Nicholson et al., "Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells," International Journal of Cancer, vol. 121, no. 3, pp. 520-527, 2007.

[196] T. J. Dorkin, M. C. Robinson, C. Marsh, A. Bjartell, D. E. Neal, and H. Y. Leung, "FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease," Oncogene, vol. 18, no. 17, pp. 2755-2761, 1999.

[197] H. Steiner, S. Godoy-Tundidor, H. Rogatsch et al., "Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway," American Journal of Pathology, vol. 162, no. 2, pp. 655-663, 2003.

[198] R. E. Bakin, D. Gioeli, E. A. Bissonette, and M. J. Weber, "Attenuation of Ras signalling restores androgen sensitivity to hormone refractory C4-2 prostate cancer cells," Cancer Research, vol. 63, no. 8, pp. 1975-1980, 2003.

[199] J. H. Jeong, Z. Wang, A. S. Guimaraes et al., "BRAF activation initiates but does not maintain invasive prostate adenocarcinoma," PLoS ONE, vol. 3, no. 12, Article ID e3949, 2008.

[200] H. B. Pearson, T. J. Phesse, and A. R. Clarke, "K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse," Cancer Research, vol. 69, no. 1, pp. 94-101, 2009.

[201] N. Palanisamy, B. Ateeq, S. Kalyana-Sundaram et al., "Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma," Nature Medicine, vol. 16, no. 7, pp. 793-798, 2010.

[202] L. Tie, N. Lu, X. Y. Pan et al., "Hypoxia-induced up-regulation of aquaporin-1 protein in prostate cancer cells in a p38-dependent manner," Cellular Physiology and Biochemistry, vol. 29, pp. 269-280, 2012.

[203] Y. Limami, A. Pinon, D. Y. Leger et al., "The P2Y2/Src/p38/ COX-2 pathway is involved in the resistance to ursolic acid-induced apoptosis in colorectal and prostate cancer cells," Biochimie, vol. 94, pp. 1754-1763, 2012.

[204] M. Katoh, "FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies," Journal of Investigative Dermatology, vol. 129, no. 8, pp. 1861-1867, 2009.

[205] P. C. Marker, A. A. Donjacour, R. Dahiya, and G. R. Cunha, "Hormonal, cellular, and molecular control of prostatic development," Developmental Biology, vol. 253, no. 2, pp. 165-174, 2003.

[206] A. A. Donjacour, A. A. Thomson, and G. R. Cunha, "FGF-10 plays an essential role in the growth of the fetal prostate," Developmental Biology, vol. 261, no. 1, pp. 39-54, 2003.

[207] Y. Lin, G. Liu, Y. Zhang et al., "Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis," Development, vol. 134, no. 4, pp. 723-734, 2007

[208] Y. Zhang, J. Zhang, Y. Lin et al., "Role of epithelial cell fibroblast growth factor receptor substrate 2a in prostate development, regeneration and tumorigenesis," Development, vol. 135, no. 4, pp. 775-784, 2008.

[209] S. L. Kuslak and P. C. Marker, "Fibroblast growth factor receptor signaling through MEK-ERK is required for prostate bud induction," Differentiation, vol. 75, no. 7, pp. 638-651, 2007

[210] M. J. Hour, S. C. Tsai, H. C. Wu et al., "Antitumor effects of the novel quinazolinone MJ-33: inhibition of metastasis through the MAPK, AKT, NF-kappaB and AP-1 signaling pathways in DU145 human prostate cancer cells," International Journal of Oncology, 2012.

[211] T. Shimizu, A. W. Tolcher, K. P. Papadopoulos et al., "The clinical effect of the dual-targeting strategy involving PI3K/AKT/ mTOR and RAS/MEK/ERK pathways in patients with advanced cancer," Clinical Cancer Research, vol. 18, pp. 2316-2325, 2012.

[212] G. C. Blobe, W. P. Schiemann, and H. F. Lodish, "Role of transforming growth factor [beta] in human disease," New England Journal of Medicine, vol. 342, no. 18, pp. 1350-1358, 2000.

[213] J. Massague, S. W. Blain, and R. S. Lo, "TGF[beta] signaling in growth control, cancer, and heritable disorders," Cell, vol. 103, no. 2, pp. 295-309, 2000.

[214] B. Schmierer and C. S. Hill, "TGF[beta]-SMAD signal transduction: molecular specificity and functional flexibility," Nature Reviews Molecular Cell Biology, vol. 8, no. 12, pp. 970-982, 2007.

[215] J. Massague, "TGFbeta in cancer," Cell, vol. 134, pp. 215-230, 2008.

[216] Y. Shi and J. Massague, "Mechanisms of TGF-[beta] signaling from cell membrane to the nucleus," Cell, vol. 113, no. 6, pp. 685-700, 2003.

[217] F. L. Miles, N. S. Tung, A. A. Aguiar, S. Kurtoglu, and R. A. Sikes, "Increased TGF-beta1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with Smad2/3 signaling," Prostate, vol. 72, pp. 1339-1350, 2012.

[218] M. K. Donkor, A. Sarkar, and M. O. Li, "Tgf-beta1 produced by activated [CD4.sup.+] T cells antagonizes T cell surveillance of tumor development," Oncoimmunology, vol. 1, pp. 162-171, 2012.

[219] X. Wan, Z. G. Li, J. M. Yingling et al., "Effect of transforming growth factor beta (TGF-beta) receptor I kinase inhibitor on prostate cancer bone growth," Bone, vol. 50, pp. 695-703, 2012.

[220] P. Wikstrom, P. Stattin, I. Franck-Lissbrant, J. E. Damber, and A. Bergh, "Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer," Prostate, vol. 37, pp. 19-29,1998.

[221] H. L. Adler, M. A. McCurdy, M. W. Kattan, T. L. Timme, P. T. Scardino, and T. C. Thompson, "Elevated levels of circulating interleukin-6 and transforming growth factor-[beta]1 in patients with metastatic prostatic carcinoma," Journal of Urology, vol. 161, no. 1, pp. 182-187, 1999.

[222] S. F. Shariat, M. Shalev, A. Menesses-Diaz et al., "Preoperative plasma levels of transforming growth factor beta1 (TGF-[beta]1 strongly predict progression in patients undergoing radical prostatectomy," Journal of Clinical Oncology, vol. 19, no. 11, pp. 2856-2864, 2001.

[223] R. Derynck, R. J. Akhurst, and A. Balmain, "TGF-[beta] signaling in tumor suppression and cancer progression," Nature Genetics, vol. 29, no. 2, pp. 117-129, 2001.

[224] L. M. Wakefield and A. B. Roberts, "TGF-[beta] signaling: positive and negative effects on tumorigenesis," Current Opinion in Genetics and Development, vol. 12, no. 1, pp. 22-29, 2002.

[225] J. Yang, R. Wahdan-Alaswad, and D. Danielpour, "Critical role of smad2 in tumor suppression and transforming growth factor-[beta]-induced apoptosis of prostate epithelial cells," Cancer Research, vol. 69, no. 6, pp. 2185-2190, 2009.

[226] L. Ye, H. Kynaston, and W. G. Jiang, "Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway," Journal of Urology, vol. 181, no. 6, pp. 2749-2759, 2009.

[227] B. T. Vo and S. A. Khan, "Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration," Prostate, vol. 71, no. 10, pp. 1084-1096,2011.

[228] H. Y. Kang, H. Y. Huang, C. Y. Hsieh et al., "Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer," Journal of Bone and Mineral Research, vol. 24, no. 7, pp. 1180-1193, 2009.

[229] J. L. Whyte, A. A. Smith, and J. A. Helms, "Wnt signaling and injury repair," Cold Spring Harbor Perspectives in Biology, vol. 4, Article ID a008078, 2012.

[230] S. Angers and R. T. Moon, "Proximal events in Wnt signal transduction," Nature Reviews Molecular Cell Biology, vol. 10, no. 7, pp. 468-477, 2009.

[231] S. Thiele, M. Rauner, C. Goettsch et al., "Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates," Journal of Cellular Biochemistry, vol. 112, no. 6, pp. 1593-1600, 2011.

[232] W. Lu, H. N. Tinsley, A. Keeton, Z. Qu, G. A. Piazza, and Y. Li, "Suppression of Wnt/[beta]-catenin signaling inhibits prostate cancer cell proliferation," European Journal of Pharmacology, vol. 602, no. 1, pp. 8-14, 2009.

[233] C. L. Hall, S. Kang, O. A. MacDougald, and E. T. Keller, "Role of Wnts in prostate cancer bone metastases," Journal of Cellular Biochemistry, vol. 97, no. 4, pp. 661-672, 2006.

[234] D. Kimelman and W. Xu, "[beta]-Catenin destruction complex: insights and questions from a structural perspective," Oncogene, vol. 25, no. 57, pp. 7482-7491, 2006.

[235] J. Huelsken and J. Behrens, "The Wnt signalling pathway," Journal of Cell Science, vol. 115, no. 21, pp. 3977-3978, 2002.

[236] H. C. Whitaker, J. Girling, A. Y. Warren, H. Leung, I. G. Mills, and D. E. Neal, "Alterations in [beta]-catenin expression and localization in prostate cancer," Prostate, vol. 68, no. 11, pp. 1196-1205, 2008.

[237] S. Majid, S. Saini, and R. Dahiya, "Wnt signaling pathways in urological cancers: past decades and still growing," Molecular Cancer, vol. 11, article 7, 2012.

[238] S. Barolo, "Transgenic Wnt/TCF pathway reporters: all you need is Lef?" Oncogene, vol. 25, no. 57, pp. 7505-7511, 2006.

[239] C. Mosimann, G. Hausmann, and K. Basler, "[beta]-Catenin hits chromatin: regulation of Wnt target gene activation," Nature Reviews Molecular Cell Biology, vol. 10, no. 4, pp. 276-286,2009.

[240] J. Zhao, W Yue, M. J. Zhu, N. Sreejayan, and M. Du, "AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552," Biochemical and Biophysical Research Communications, vol. 395, no. 1, pp. 146-151, 2010.

[241] W. J. Gullick, "Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers," British Medical Bulletin, vol. 47, no. 1, pp. 87-98,1991.

[242] K. K. Guturi, T. Mandal, A. Chatterjee et al., "Mechanism of beta-catenin-mediated transcriptional regulation of epidermal growth factor receptor expression in glycogen synthase kinase 3 beta-inactivated prostate cancer cells," Journal of Biological Chemistry, vol. 287, pp. 18287-18296, 2012.

[243] P. C. Marker, "Does prostate cancer co-opt the developmental program?" Differentiation, vol. 76, no. 6, pp. 736-744, 2008.

[244] N. S. Fearnhead, M. P. Britton, and W. F. Bodmer, "The ABC of APC," Human Molecular Genetics, vol. 10, no. 7, pp. 721-733, 2001.

[245] D. R. Chesire, C. M. Ewing, J. Sauvageot, G. S. Bova, and W. B. Isaacs, "Detection and analysis of beta-catenin mutations in prostate cancer," Prostate, vol. 45, pp. 323-334, 2000.

[246] L. Richiardi, V. Fiano, L. Vizzini et al., "Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients," Journal of Clinical Oncology, vol. 27, no. 19, pp. 3161-3168, 2009.

[247] L. E. Pascal, R. Z. N. Vencio, L. S. Page et al., "Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes," BMC Cancer, vol. 9, article 452, 2009.

[248] C. M. Koh, C. J. Bieberich, C. V. Dang, W. G. Nelson, S. Yegnasubramanian, and A. M. De Marzo, "MYC and prostate cancer," Genes and Cancer, vol. 1, no. 6, pp. 617-628, 2010.

[249] J. P. Alao, "The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention," Molecular Cancer, vol. 6, article 24, 2007

[250] T. Grigoryan, P. Wend, A. Klaus, and W. Birchmeier, "Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of [beta]-catenin in mice," Genes and Development, vol. 22, no. 17, pp. 2308-2341, 2008.

[251] C. L. Hall, A. Bafico, J. Dai, S. A. Aaronson, and E. T. Keller, "Prostate cancer cells promote osteoblastic bone metastases through Wnts," Cancer Research, vol. 65, no. 17, pp. 7554-7560, 2005.

[252] K. J. Bruxvoort, H. M. Charbonneau, T. A. Giambernardi et al., "Inactivation of Apc in the mouse prostate causes prostate carcinoma," Cancer Research, vol. 67, no. 6, pp. 2490-2496,2007

[253] P. Uysal-Onganer, Y. Kawano, M. Caro et al., "Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells," Molecular Cancer, vol. 9, article 55, 2010.

[254] S. Gupta, K. Iljin, H. Sara et al., "FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells," Cancer Research, vol. 70, no. 17, pp. 6735-6745, 2010.

[255] M. A. Liss, M. Schlicht, A. Kahler et al., "Characterization of soy-based changes in Wnt-frizzled signaling in prostate cancer," Cancer Genomics and Proteomics, vol. 7, no. 5, pp. 245-252,2010.

[256] D. R. Chesire and W. B. Isaacs, "[beta]-Catenin signaling in prostate cancer: an early perspective," Endocrine-Related Cancer, vol. 10, no. 4, pp. 537-560, 2003.

[257] B. He, L. You, K. Uematsuet al., "A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells," Neoplasia, vol. 6, no. 1, pp. 7-14, 2004.

[258] G. W. Yardy and S. F. Brewster, "Wnt signalling and prostate cancer," Prostate Cancer and Prostatic Diseases, vol. 8, no. 2, pp. 119-126, 2005.

[259] S. Le Guellec, I. Soubeyran, P. Rochaix et al., "CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics," Modern Pathology, vol. 25, pp. 1551-1558, 2012.

[260] K. Willert, J. D. Brown, E. Danenberg et al., "Wnt proteins are lipid-modified and can act as stem cell growth factors," Nature, vol. 423, no. 6938, pp. 448-452, 2003.

[261] M. Sharma, W. W. Chuang, and Z. Sun, "Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3[beta] inhibition and nuclear [beta]-catenin accumulation," Journal of Biological Chemistry, vol. 277, no. 34, pp. 30935-30941, 2002.

[262] P. Polakis, "The many ways of Wnt in cancer," Current Opinion in Genetics and Development, vol. 17, no. 1, pp. 45-51, 2007

[263] P. Wend, J. D. Holland, U. Ziebold, and W. Birchmeier, "Wnt signaling in stem and cancer stem cells," Seminars in Cell and Developmental Biology, vol. 21, no. 8, pp. 855-863, 2010.

[264] T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, "Stem cells, cancer, and cancer stem cells," Nature, vol. 414, no. 6859, pp. 105-111, 2001.

[265] M. D. Castellone, H. Teramoto, B. O. Williams, K. M. Druey, and J. S. Gutkind, "Medicine: prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-[beta]-catenin signaling axis," Science, vol. 310, no. 5753, pp. 1504-1510, 2005.

[266] M. Lepourcelet, Y. N. P. Chen, D. S. France et al., "Small-molecule antagonists of the oncogenic Tcf/[beta]-catenin protein complex," Cancer Cell, vol. 5, no. 1, pp. 91-102, 2004.

[267] J. P. Rey and D. L. Ellies, "Wnt modulators in the biotech pipeline," Developmental Dynamics, vol. 239, no. 1, pp. 102-114,2010.

Henrique B. da Silva, (1) Eduardo P. Amaral, (1) Eduardo L. Nolasco, (2) Nathalia C. de Victo, (1) Rodrigo Atique, (3) Carina C. Jank, (1,4) Valesca Anschau, (3) Luiz F. Zerbini, (5) and Ricardo G. Correa (6)

(1) Departamento de Imunologia, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Avenida Prof. Lineu Prestes 1730, 05508-900 Sao Paulo, SP, Brazil

(2) Departamento de Analises ClOnicas e Toxicologicas, Faculdade de Ciencias Farmaceuticas, Universidade de Sao Paulo, Avenida Prof. Lineu Prestes 580, 05508-000 Sao Paulo, SP, Brazil

(3) Departamento de Genetica eBiologia Evolutiva, Instituto deBiociencias, Universidade de Sao Paulo, Rua do Matao 277, 05508-900 Sao Paulo, SP, Brazil

(4) Instituto Israelita de Ensino e Pesquisa Albert Einstein, Avenida Albert Einstein 627/701, 05652-000 Sao Paulo, SP, Brazil

(5) International Center for Genetic Engineering & Biotechnology (ICGEB), Cancer Genomics Group and Division of Medical Biochemistry, University of Cape Town, Cape Town 7925, South Africa

(6) Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA

Correspondence should be addressed to Ricardo G. Correa;

Received 30 November 2012; Revised 25 March 2013; Accepted 28 March 2013

Academic Editor: Craig Robson
COPYRIGHT 2013 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:da Silva, Henrique B.; Amaral, Eduardo P.; Nolasco, Eduardo L.; de Victo, Nathalia C.; Atique, Rodri
Publication:Prostate Cancer
Date:Jan 1, 2013
Previous Article:A pilot study of laparoscopic Doppler ultrasound probe to map arterial vascular flow within the neurovascular bundle during robot-assisted radical...
Next Article:Emerging molecularly targeted therapies in castration refractory prostate cancer.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters